<!DOCTYPE html>
<html class="no-js" lang="en">
<head>
  <meta charset="utf-8" />
  <meta http-equiv="x-ua-compatible" content="ie=edge" />
  <title>
    PharmCAT Report [pharmcat.example]
  </title>

  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <!-- HTML5 shim and Respond.js for IE8 support of HTML5 elements and media queries -->
  <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
  <!--[if lt IE 9]>
  <script src="https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js"></script>
  <script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
  <![endif]-->
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" />
  <style>
    html {
      font-size: 16px;
      background-color: #666666;
    }
    body {
      font-weight: 300;
      -moz-osx-font-smoothing: grayscale;
      -webkit-font-smoothing: antialiased;
      line-height: 1.5;
      font-size: 1rem;
      font-family: "Museo Sans W01 Rounded",Arial,Helvetica,sans-serif;
      color: rgb(25, 31, 42);
      background-color: #ffffff;
      margin: 0 auto;
      max-width: 70em;
      padding: 0;
    }
    header {
      margin-bottom: 1em;
    }
    main {
      margin: 1em 1em 0 1em;
      padding-bottom: 2em;
    }
    h1, h2, h3, h4 {
      margin-top: 0.5rem;
      margin-bottom: 0.5rem;
    }
    a, h1, h2, h3, h4, h5, h6 {
      color: #3e4c6c;
    }
    h1 {
      font-size: 2em;
      font-weight: 100;
    }
    h2, h3, h4 {
      font-weight: 300;
    }
    h2 {
      font-size: 1.8em;
    }
    h3 {
      font-size: 1.5em;
    }
    h4 {
      font-size: 1.2em;
    }
    p {
      margin-top: 0;
      margin-bottom: 1em;
    }
    section {
      margin-bottom: 2.5rem;
    }
    table, ul {
      margin-bottom: 1.5rem;
    }
    table {
      min-width: 100%;
      border-collapse: collapse;
      border-color: grey;
      font-size: 0.9rem;
    }
    td, th {
      border: 1px solid rgba(62, 76, 108, 0.1);
      max-width: 600px;
      word-wrap: break-word;
      padding: 1em 1.3em;
    }
    td p:last-child {
      margin-bottom: 0;
    }
    th {
      text-align: left;
    }
    tr.top-aligned td,th {
      vertical-align: top;
    }
    .table-small th {
      font-weight: normal;
      font-style: italic;
      width: 10em;
    }
    .table-small th, .table-small td {
      padding:.2em;
      font-size: .8em;
      border: 0;
    }
    table.diplotype {
      margin-bottom: 0;
    }
    table.genotypeSummary thead th {
      padding-bottom: 0;
    }
    table.diplotype td {
      width: 33%;
      padding: .2em .2em .2em 1em;
      border-width: 1px 0 0 0;
    }
    table.diplotype tbody tr:first-child td {
      border-top: 0;
    }
    tr.leastFunctionDiplotype td {
      color: #3f3f3f;
    }
    tr.leastFunctionDiplotype + tr td {
      border-top: 0;
    }
    table.diplotype tbody tr td:first-child {
      padding: .2em;
      border-left-width: 0;
    }
    table.diplotype tbody tr td {
      border-left-width: 1px;
    }


    .pageHeader {
      display: flex;
      align-items: center;
      padding: 1em 1em;
      background-color: #3e4c6c;
      color: #ffffff;
      min-width: 20em;
    }
    .pageHeader .title {
      font-weight: bold;
      font-size: 2em;
      min-width: 10em;
      width: 30%;
    }
    .pageHeader .subtitle {
      margin-left: .5em;
      font-size: .75em;
    }
    .pageHeader .metadata {
      min-width: 10em;
      width: 69%;
    }
    .pageHeader .metadata table {
      line-height: 1;
      margin: 0 .5em 0 auto;
      min-width: unset;
    }
    .pageHeader .metadata th {
      padding: 0 .5em 0 0;
      font-size: .8em;
      font-style: normal;
      font-weight: normal;
      text-align: right;
      vertical-align: top;
      white-space: nowrap;
    }
    .pageHeader .metadata td {
      font-size: .8em;
      padding: 0;
      vertical-align: top;
    }

    .missingVariantsNote {
      margin-top: 1.2em;
      margin-bottom: 0;
      font-size: 0.9em;
    }

    hr {
      margin-bottom: 2em;
    }
    section.gene, section.guideline {
      margin-top: 2em;
      margin-bottom: 2em;
      border-bottom: 1px solid #DDD;
    }
    section.gene:last-child, section.guideline:last-child {
      border-bottom: 0;
    }

    ol.noPadding, ul.noPadding {
      padding-inline-start: 1rem;
    }
    ol.noBullet, ul.noBullet {
      list-style-type: none;
      padding-left: 0;
    }

    dl.compact dd {
      margin-left: 1em;
    }

    div.hint {
      text-transform: capitalize;
      font-size: .8em;
      color: #666666;
    }

    .alert {
      margin: 1em 0;
      padding: 0.6em;
      border-radius: 4px;
      text-shadow: 0 1px 0 rgba(255, 255, 255, 0.5);
      print-color-adjust: exact !important;
    }
    .alert-info {
      background-color: #d9edf7;
      border-color: #bce8f1;
      color: #3a87ad;
    }
    .alert-warning {
      background-color: #fcf8e3;
      border-color: #faebcc;
      color: #8a6d3b;
    }
    .alert-danger {
      background-color: #EAD6D5;
      border-color: #EFDFDE;
      color: #7C3A37;
    }
    .alert-danger h4 {
      color: #7C3A37;
      font-weight: bold;
    }

    .noGeneData {
      font-size: .8em;
      margin: 0 0.5em;
    }
    .drugName, .noWrap {
      white-space: nowrap;
    }
    .normalWrap {
      white-space: normal;
    }

    td.missingVariant {
      background-color: lightsalmon;
      print-color-adjust: exact !important;
    }

    td.mismatch {
      background-color: palegoldenrod;
      print-color-adjust: exact !important;
    }

    .mt-0 {
      margin-top: 0;
    }
    .mt-1 {
      margin-top: 1em;
    }
    
    div.callMessage {
      font-style: italic;
      font-weight: normal;
    }
    
    .geneCall {
      font-size: 1.2em;
    }

    .footnote {
      padding: .25em .5em;
      font-size: .8em;
    }
    .citations {
      font-size: .9em;
    }
    .footnote + .citations {
      margin-top: 1.5rem;
    }
    .sources {
      font-size: .8em;
    }
    .smallFont {
      font-size: .9em;
    }

    .footnote sup {
      font-style: normal;
    }

    #liability {
      font-size: 1.2em;
      color: darkred;
    }

    .warfarinFlowchart {
      text-align: center;
    }
    .warfarinFlowchart img {
      width: 100%;
      height: auto;
    }

    .nonwild {
      font-weight: bold;
    }

    .warningList {
      margin: 0;
      list-style: none;
      padding-left: 0;
    }

    sup a {
      text-decoration: none;
    }

    @media print {
      html {
        font-size: 8px;
      }

      a {
        text-decoration: none;
      }

      img, pre, blockquote, table, figure, p {
        page-break-inside: avoid;
      }
    }
  </style>


</head>
<body>
<!--[if lt IE 9]>
<p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->
<header class="pageHeader">
  <div class="title">
    PharmCAT Report
    <div class="subtitle">pharmcat.example</div>
  </div>
  <div class="metadata">
    <table>
      <tr><th>Date created</th><td>October 20, 2022</td></tr>
      <tr><th>PharmCAT Version</th><td>v2.0.0</td></tr>
      <tr><th>CPIC Version</th><td>v1.21.0</td></tr>
    </table>
  </div>
</header>
<main>
  <section>
    <h2>Sections</h2>
    <ol type="I">
      <li><a href="#section-i">Genotype Summary</a></li>
      <li><a href="#section-ii">Prescribing Recommendations</a></li>
      <li><a href="#section-iii">Allele Matching Details</a></li>
      <li><a href="#disclaimer">Disclaimers</a></li>
    </ol>

    <div class="alert alert-info">
      <em>Disclaimer:</em> PharmCAT is only able to generate recommendations based on the information provided to the
      software. The gene and variant information for all reported sections are interpreted directly from user-supplied data.
      The user recognizes they are using PharmCAT at their own risk. For a detailed disclaimer see
      <a href="#disclaimer">Section IV</a>.
    </div>
  </section>


  <section id="section-i">
    <h2>Section I: Genotype Summary</h2>

    <p>Genotypes called: 21 / 23 </p>

    
      <table class="genotypeSummary">
        <thead>
        <tr>
          <th>Drugs</th>
          <th>Gene</th>
          <th>
            Genotypes
            <table class="diplotype table-small">
              <tbody>
              <tr>
                <td>Genotype</td>
                <td>Allele Functionality</td>
                <td>Phenotype</td>
              </tr>
              </tbody>
            </table>
          </th>
        </tr>
        </thead>
        <tbody>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#allopurinol">allopurinol</a></div>
                
              
                
                  <div class="drugName"><a href="#rosuvastatin">rosuvastatin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#ABCG2" class="normalWrap">ABCG2</a>
                
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>rs2231142 reference (G)/rs2231142 reference (G)</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Function</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#desflurane">desflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#enflurane">enflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#halothane">halothane</a></div>
                
              
                
                  <div class="drugName"><a href="#isoflurane">isoflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#methoxyflurane">methoxyflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#sevoflurane">sevoflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#succinylcholine">succinylcholine</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CACNA1S" class="normalWrap">CACNA1S</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>Reference/Reference</td>
                      <td>Two normal function alleles</td>
                      <td>Uncertain Susceptibility</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#ivacaftor">ivacaftor</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CFTR" class="normalWrap">CFTR</a>
                
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>No CPIC variants found</td>
                      <td>Two ivacaftor non-responsive alleles</td>
                      <td>ivacaftor non-responsive in CF patients</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#efavirenz">efavirenz</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP2B6" class="normalWrap">CYP2B6</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#amitriptyline">amitriptyline</a></div>
                
              
                
                  <div class="drugName"><a href="#citalopram">citalopram</a></div>
                
              
                
                  <div class="drugName"><a href="#clomipramine">clomipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#clopidogrel">clopidogrel</a></div>
                
              
                
                  <div class="drugName"><a href="#dexlansoprazole">dexlansoprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#doxepin">doxepin</a></div>
                
              
                
                  <div class="drugName"><a href="#escitalopram">escitalopram</a></div>
                
              
                
                  <div class="drugName"><a href="#imipramine">imipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#lansoprazole">lansoprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#omeprazole">omeprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#pantoprazole">pantoprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#sertraline">sertraline</a></div>
                
              
                
                  <div class="drugName"><a href="#trimipramine">trimipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#voriconazole">voriconazole</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP2C19" class="normalWrap">CYP2C19</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*38/*38</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#celecoxib">celecoxib</a></div>
                
              
                
                  <div class="drugName"><a href="#flurbiprofen">flurbiprofen</a></div>
                
              
                
                  <div class="drugName"><a href="#fluvastatin">fluvastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#fosphenytoin">fosphenytoin</a></div>
                
              
                
                  <div class="drugName"><a href="#ibuprofen">ibuprofen</a></div>
                
              
                
                  <div class="drugName"><a href="#lornoxicam">lornoxicam</a></div>
                
              
                
                  <div class="drugName"><a href="#meloxicam">meloxicam</a></div>
                
              
                
                  <div class="drugName"><a href="#phenytoin">phenytoin</a></div>
                
              
                
                  <div class="drugName"><a href="#piroxicam">piroxicam</a></div>
                
              
                
                  <div class="drugName"><a href="#siponimod">siponimod</a></div>
                
              
                
                  <div class="drugName"><a href="#tenoxicam">tenoxicam</a></div>
                
              
                
                  <div class="drugName"><a href="#warfarin">warfarin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP2C9" class="normalWrap">CYP2C9</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#amitriptyline">amitriptyline</a></div>
                
              
                
                  <div class="drugName"><a href="#aripiprazole">aripiprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#atomoxetine">atomoxetine</a></div>
                
              
                
                  <div class="drugName"><a href="#brexpiprazole">brexpiprazole</a></div>
                
              
                
                  <div class="drugName"><a href="#clomipramine">clomipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#codeine">codeine</a></div>
                
              
                
                  <div class="drugName"><a href="#desipramine">desipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#doxepin">doxepin</a></div>
                
              
                
                  <div class="drugName"><a href="#eliglustat">eliglustat</a></div>
                
              
                
                  <div class="drugName"><a href="#flecainide">flecainide</a></div>
                
              
                
                  <div class="drugName"><a href="#fluvoxamine">fluvoxamine</a></div>
                
              
                
                  <div class="drugName"><a href="#haloperidol">haloperidol</a></div>
                
              
                
                  <div class="drugName"><a href="#hydrocodone">hydrocodone</a></div>
                
              
                
                  <div class="drugName"><a href="#imipramine">imipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#metoprolol">metoprolol</a></div>
                
              
                
                  <div class="drugName"><a href="#nortriptyline">nortriptyline</a></div>
                
              
                
                  <div class="drugName"><a href="#ondansetron">ondansetron</a></div>
                
              
                
                  <div class="drugName"><a href="#paroxetine">paroxetine</a></div>
                
              
                
                  <div class="drugName"><a href="#pimozide">pimozide</a></div>
                
              
                
                  <div class="drugName"><a href="#propafenone">propafenone</a></div>
                
              
                
                  <div class="drugName"><a href="#risperidone">risperidone</a></div>
                
              
                
                  <div class="drugName"><a href="#tamoxifen">tamoxifen</a></div>
                
              
                
                  <div class="drugName"><a href="#tramadol">tramadol</a></div>
                
              
                
                  <div class="drugName"><a href="#trimipramine">trimipramine</a></div>
                
              
                
                  <div class="drugName"><a href="#tropisetron">tropisetron</a></div>
                
              
                
                  <div class="drugName"><a href="#venlafaxine">venlafaxine</a></div>
                
              
                
                  <div class="drugName"><a href="#zuclopenthixol">zuclopenthixol</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP2D6" class="normalWrap">CYP2D6</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*3</td>
                      <td>One no function allele and one normal function allele</td>
                      <td>Intermediate Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#quetiapine">quetiapine</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP3A4" class="normalWrap">CYP3A4</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#tacrolimus">tacrolimus</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP3A5" class="normalWrap">CYP3A5</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#warfarin">warfarin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#CYP4F2" class="normalWrap">CYP4F2</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>N/A</td>
                      <td>N/A</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#capecitabine">capecitabine</a></div>
                
              
                
                  <div class="drugName"><a href="#flucytosine">flucytosine</a></div>
                
              
                
                  <div class="drugName"><a href="#fluorouracil">fluorouracil</a></div>
                
              
                
                  <div class="drugName"><a href="#tegafur">tegafur</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#DPYD" class="normalWrap">DPYD</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  
                    <tr class="leastFunctionDiplotype">
                      <td colspan="3"><b>Reference/Reference</b></td>
                    </tr>
                  
                  
                    <tr class="top-aligned">
                      <td>Reference</td>
                      <td>normal function</td>
                      <td>See drug section</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#aminosalicylic acid">aminosalicylic acid</a></div>
                
              
                
                  <div class="drugName"><a href="#aspirin">aspirin</a></div>
                
              
                
                  <div class="drugName"><a href="#chloramphenicol">chloramphenicol</a></div>
                
              
                
                  <div class="drugName"><a href="#chloroquine">chloroquine</a></div>
                
              
                
                  <div class="drugName"><a href="#ciprofloxacin">ciprofloxacin</a></div>
                
              
                
                  <div class="drugName"><a href="#dapsone">dapsone</a></div>
                
              
                
                  <div class="drugName"><a href="#dimercaprol">dimercaprol</a></div>
                
              
                
                  <div class="drugName"><a href="#doxorubicin">doxorubicin</a></div>
                
              
                
                  <div class="drugName"><a href="#furazolidone">furazolidone</a></div>
                
              
                
                  <div class="drugName"><a href="#glyburide">glyburide</a></div>
                
              
                
                  <div class="drugName"><a href="#hydroxychloroquine">hydroxychloroquine</a></div>
                
              
                
                  <div class="drugName"><a href="#mafenide">mafenide</a></div>
                
              
                
                  <div class="drugName"><a href="#methylene blue">methylene blue</a></div>
                
              
                
                  <div class="drugName"><a href="#nalidixic acid">nalidixic acid</a></div>
                
              
                
                  <div class="drugName"><a href="#nitrofurantoin">nitrofurantoin</a></div>
                
              
                
                  <div class="drugName"><a href="#norfloxacin">norfloxacin</a></div>
                
              
                
                  <div class="drugName"><a href="#ofloxacin">ofloxacin</a></div>
                
              
                
                  <div class="drugName"><a href="#pegloticase">pegloticase</a></div>
                
              
                
                  <div class="drugName"><a href="#phenazopyridine">phenazopyridine</a></div>
                
              
                
                  <div class="drugName"><a href="#primaquine">primaquine</a></div>
                
              
                
                  <div class="drugName"><a href="#quinine">quinine</a></div>
                
              
                
                  <div class="drugName"><a href="#rasburicase">rasburicase</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfadiazine">sulfadiazine</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfadimidine">sulfadimidine</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfamethoxazole / trimethoprim">sulfamethoxazole / trimethoprim</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfanilamide">sulfanilamide</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfasalazine">sulfasalazine</a></div>
                
              
                
                  <div class="drugName"><a href="#sulfisoxazole">sulfisoxazole</a></div>
                
              
                
                  <div class="drugName"><a href="#tafenoquine">tafenoquine</a></div>
                
              
                
                  <div class="drugName"><a href="#tolbutamide">tolbutamide</a></div>
                
              
                
                  <div class="drugName"><a href="#toluidine blue">toluidine blue</a></div>
                
              
                
                  <div class="drugName"><a href="#vitamin c">vitamin c</a></div>
                
              
                
                  <div class="drugName"><a href="#vitamin k">vitamin k</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#G6PD" class="normalWrap">G6PD</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>B (wildtype)/B (wildtype)</td>
                      <td>Two unassigned function alleles</td>
                      <td>N/A</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#abacavir">abacavir</a></div>
                
              
                
                  <div class="drugName"><a href="#allopurinol">allopurinol</a></div>
                
              
                
                  <div class="drugName"><a href="#carbamazepine">carbamazepine</a></div>
                
              
                
                  <div class="drugName"><a href="#fosphenytoin">fosphenytoin</a></div>
                
              
                
                  <div class="drugName"><a href="#oxcarbazepine">oxcarbazepine</a></div>
                
              
                
                  <div class="drugName"><a href="#phenytoin">phenytoin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#HLA-B" class="normalWrap">HLA-B</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*15:02/*57:01</td>
                      <td>N/A</td>
                      <td>*15:02 positive; *57:01 positive; *58:01 negative</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#peginterferon alfa-2a">peginterferon alfa-2a</a></div>
                
              
                
                  <div class="drugName"><a href="#peginterferon alfa-2b">peginterferon alfa-2b</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#IFNL3/4" class="normalWrap">IFNL3/4</a>
                
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>rs12979860 reference (C)/rs12979860 reference (C)</td>
                      <td>N/A</td>
                      <td>N/A</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#amikacin">amikacin</a></div>
                
              
                
                  <div class="drugName"><a href="#gentamicin">gentamicin</a></div>
                
              
                
                  <div class="drugName"><a href="#kanamycin">kanamycin</a></div>
                
              
                
                  <div class="drugName"><a href="#paromomycin">paromomycin</a></div>
                
              
                
                  <div class="drugName"><a href="#plazomicin">plazomicin</a></div>
                
              
                
                  <div class="drugName"><a href="#streptomycin">streptomycin</a></div>
                
              
                
                  <div class="drugName"><a href="#tobramycin">tobramycin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#MT-RNR1" class="normalWrap">MT-RNR1</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>1555A&gt;G</td>
                      <td>increased risk of aminoglycoside-induced hearing loss</td>
                      <td>increased risk of aminoglycoside-induced hearing loss</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#azathioprine">azathioprine</a></div>
                
              
                
                  <div class="drugName"><a href="#mercaptopurine">mercaptopurine</a></div>
                
              
                
                  <div class="drugName"><a href="#thioguanine">thioguanine</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#NUDT15" class="normalWrap">NUDT15</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#desflurane">desflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#enflurane">enflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#halothane">halothane</a></div>
                
              
                
                  <div class="drugName"><a href="#isoflurane">isoflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#methoxyflurane">methoxyflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#sevoflurane">sevoflurane</a></div>
                
              
                
                  <div class="drugName"><a href="#succinylcholine">succinylcholine</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#RYR1" class="normalWrap">RYR1</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>Reference/Reference</td>
                      <td>Two normal function alleles</td>
                      <td>Uncertain Susceptibility</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#atorvastatin">atorvastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#fluvastatin">fluvastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#lovastatin">lovastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#pitavastatin">pitavastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#pravastatin">pravastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#rosuvastatin">rosuvastatin</a></div>
                
              
                
                  <div class="drugName"><a href="#simvastatin">simvastatin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#SLCO1B1" class="normalWrap">SLCO1B1</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Function</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#azathioprine">azathioprine</a></div>
                
              
                
                  <div class="drugName"><a href="#mercaptopurine">mercaptopurine</a></div>
                
              
                
                  <div class="drugName"><a href="#thioguanine">thioguanine</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#TPMT" class="normalWrap">TPMT</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#atazanavir">atazanavir</a></div>
                
              
                
                  <div class="drugName"><a href="#irinotecan">irinotecan</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#UGT1A1" class="normalWrap">UGT1A1</a>
                <sup><a href="#genotypes-dagger">&dagger;</a></sup>
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>*1/*1</td>
                      <td>Two normal function alleles</td>
                      <td>Normal Metabolizer</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
          <tr class="top-aligned">
            <td>
              
                
                  <div class="drugName"><a href="#acenocoumarol">acenocoumarol</a></div>
                
              
                
                  <div class="drugName"><a href="#phenprocoumon">phenprocoumon</a></div>
                
              
                
                  <div class="drugName"><a href="#warfarin">warfarin</a></div>
                
              
            </td>
            <td>
              <span class="noWrap">
                <a href="#VKORC1" class="normalWrap">VKORC1</a>
                
                <sup><a href="#genotypes-ddagger">&ddagger;</a></sup>
              </span>
            </td>
            <td>
              <table class="diplotype">
                <tbody>
                
                  <!-- standard diplotype -->
                  
                    <tr class="top-aligned">
                      <td>rs9923231 reference (C)/rs9923231 reference (C)</td>
                      <td>N/A</td>
                      <td>N/A</td>
                    </tr>
                  
                
                </tbody>
              </table>
              
            </td>
          </tr>
        
        </tbody>
      </table>
      
      
        <div class="footnote" id="genotypes-dagger">
          <sup>&dagger;</sup> Check <a href="#section-iii">Section III</a> for more details about this call.
        </div>
      
      
        <div class="footnote" id="genotypes-ddagger">
          <sup>&ddagger;</sup> PharmCAT reports the genotype(s) that receive the highest score during the matcher process.
          In case of unphased data, additional genotypes might be possible and cannot be ruled out.
        </div>
      
      <div class="footnote">
        For a full list of disclaimers and limitations see the <a href="#disclaimer">Section IV</a>.
      </div>

      
      
        <div class="alert alert-info multiple-dpwg-versions">Multiple DPWG versions used to generate gene and drug reports: [2022-10-13-18-52, v1.21.0].</div>
      
    
  </section>


  <section id="section-ii">
    <h2>Section II: Prescribing Recommendations</h2>

    
      <section class="guideline abacavir">
        <h3 id="abacavir">abacavir</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:190521" class="top-aligned cpic-abacavir">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-abacavir-1-1">
                            <span class="noWrap">
                              <a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>HLA-B: Significantly increased risk of abacavir hypersensitivity</td>
                      <td>Abacavir is not recommended</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22378157" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22378157</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24561393" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24561393</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline acenocoumarol">
        <h3 id="acenocoumarol">acenocoumarol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104938" class="top-aligned dpwg-acenocoumarol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104938" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104938-1">
                            <span class="noWrap">
                              <a href="#VKORC1">VKORC1</a>:<br />rs9923231 reference (C)/<br />rs9923231 reference (C)
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>VKORC1: The guideline does not provide a description of the impact of the -1639 GG genotype on acenocoumarol.</td>
                      <td>The guideline does not provide a recommendation for acenocoumarol in patients with the VKORC1 rs9923231 CC genotype (-1639 GG genotype).</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline allopurinol">
        <h3 id="allopurinol">allopurinol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:519" class="top-aligned cpic-allopurinol">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-allopurinol-1-1">
                            <span class="noWrap">
                              <a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>HLA-B: Low or reduced risk of allopurinol-induced SCAR</td>
                      <td>Use allopurinol per standard dosing guidelines</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166264961" class="top-aligned dpwg-allopurinol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166264961" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166264961-1">
                            <span class="noWrap">
                              <a href="#ABCG2">ABCG2</a>:<br />rs2231142 reference (G)/<br />rs2231142 reference (G)
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>ABCG2: The guideline does not provide a description of the impact of the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ) on allopurinol.</td>
                      <td>The guideline does not provide a recommendation for allopurinol in patients with the the ABCG2 rs2231142 GG genotype (c.421CC; p.141QQ)</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36056234" target="_blank" rel="noopener noreferrer">Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.</a> <i>European journal of human genetics : EJHG</i>. 2022. PMID:36056234</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/26094938" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:26094938</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23232549" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:23232549</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline amikacin">
        <h3 id="amikacin">amikacin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:641" class="top-aligned cpic-amikacin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-amikacin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline aminosalicylic acid">
        <h3 id="aminosalicylic acid">aminosalicylic acid</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline amitriptyline">
        <h3 id="amitriptyline">amitriptyline</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:704" class="top-aligned cpic-amitriptyline">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-amitriptyline-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38;<br /><a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>Normal Metabolizer</dd><dt>CYP2D6:</dt><dd>Intermediate Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>N/A</dd><dt>CYP2D6:</dt><dd>1.0</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C19: Normal metabolism of tertiary amines</li><li>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects</li></ul></td>
                      <td>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104982" class="top-aligned dpwg-amitriptyline">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104982" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104982-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline.</td>
                      <td>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline aripiprazole">
        <h3 id="aripiprazole">aripiprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104937" class="top-aligned dpwg-aripiprazole">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104937" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104937-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The guideline does not provide a description of the impact of an intermediate metabolizer phenotype on aripiprazole.</td>
                      <td>NO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline aspirin">
        <h3 id="aspirin">aspirin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline atazanavir">
        <h3 id="atazanavir">atazanavir</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:343047" class="top-aligned cpic-atazanavir">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-atazanavir-1-1">
                            <span class="noWrap">
                              <a href="#UGT1A1">UGT1A1</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>UGT1A1: Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.</td>
                      <td>There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).</td>
                      <td>All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat. &quot;reference&quot; function refers to the UGT1A1 allele to which other alleles are compared.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/26417955" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:26417955</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline atomoxetine">
        <h3 id="atomoxetine">atomoxetine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:38400" class="top-aligned cpic-atomoxetine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />adults</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-atomoxetine-2-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.</td>
                      <td>Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.</td>
                      <td>Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.</td>
                      <td>Moderate</td>
                  
                
                  <tr id="#RxNorm:38400" class="top-aligned cpic-atomoxetine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />pediatrics</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-atomoxetine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.</td>
                      <td>Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.</td>
                      <td>Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104989" class="top-aligned dpwg-atomoxetine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104989" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104989-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The genetic variation increases the plasma concentration of atomoxetine and can thereby reduce the dose requirement.</td>
                      <td><ol>
<li>In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30801677" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2019. PMID:30801677</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline atorvastatin">
        <h3 id="atorvastatin">atorvastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:83367" class="top-aligned cpic-atorvastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />population general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-atorvastatin-1-1">
                            <span class="noWrap">
                              <a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-atorvastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Function</p>
                      
                      
                    </td>
                  
                      <td>SLCO1B1: Typical myopathy risk and statin exposure</td>
                      <td>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182843" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#SLCO1B1">SLCO1B1</a> *1/*1.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline azathioprine">
        <h3 id="azathioprine">azathioprine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:1256" class="top-aligned cpic-azathioprine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-azathioprine-1-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1;<br /><a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>Normal Metabolizer</dd><dt>TPMT:</dt><dd>Normal Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>N/A</dd><dt>TPMT:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</li><li>TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</li></ul></td>
                      <td>Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).</td>
                      <td>Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166184614" class="top-aligned dpwg-azathioprine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184614" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104934" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166184614-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>NUDT15: The guideline does not provide a description of the impact of a normal metabolizer phenotype on azathioprine.</td>
                      <td>The guideline does not provide a recommendation for azathioprine in normal metabolizers</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
                
                  <tr id="#PA166104934" class="top-aligned dpwg-azathioprine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184614" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104934" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104934-1">
                            <span class="noWrap">
                              <a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>TPMT: The guideline does not provide a description of the impact of a normal metabolizer phenotype on azathioprine.</td>
                      <td>The guideline does not provide a recommendation for azathioprine in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794" target="_blank" rel="noopener noreferrer">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21270794</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23422873</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30447069" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30447069</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline brexpiprazole">
        <h3 id="brexpiprazole">brexpiprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166184527" class="top-aligned dpwg-brexpiprazole">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184527" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166184527-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The guideline does not provide a description of the impact of an intermediate metabolizer phenotype on brexpiprazole.</td>
                      <td>NO action is required for this gene-drug interaction. There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline capecitabine">
        <h3 id="capecitabine">capecitabine</h3>

        
          <div class="alert alert-info DPYD-lowest-activity-score-note">The two lowest activity values (variant activity scores, see CPIC guideline PMID: 29152729) are used to determine the gene activity score and phenotype type to retrieve prescribing recommendations. </div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:194000" class="top-aligned cpic-capecitabine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-capecitabine-1-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>DPYD: Normal DPD activity and "normal" risk for fluoropyrimidine toxicity</td>
                      <td>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104963" class="top-aligned dpwg-capecitabine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104963" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104963-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2</p>
                      
                    </td>
                  
                      <td>DPYD: The guideline does not provide a description of the impact of a <em>DPYD</em> activity score of 2 on capecitabine.</td>
                      <td>The guideline does not provide a recommendation for capecitabine in patients with a <em>DPYD</em> activity score of 2.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31745289" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.</a> <i>European journal of human genetics : EJHG</i>. 2019. PMID:31745289</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23988873" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23988873</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29152729" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2017. PMID:29152729</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline carbamazepine">
        <h3 id="carbamazepine">carbamazepine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#HLA-A">HLA-A</a> Unknown/Unknown and <a href="#HLA-B">HLA-B</a> *15:02/*57:01.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23695185" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23695185</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29392710" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:29392710</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline celecoxib">
        <h3 id="celecoxib">celecoxib</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:140587" class="top-aligned cpic-celecoxib">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-celecoxib-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline chloramphenicol">
        <h3 id="chloramphenicol">chloramphenicol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline chloroquine">
        <h3 id="chloroquine">chloroquine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline ciprofloxacin">
        <h3 id="ciprofloxacin">ciprofloxacin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline citalopram">
        <h3 id="citalopram">citalopram</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:2556" class="top-aligned cpic-citalopram">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-citalopram-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104977" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34782755" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34782755</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25974703</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline clomipramine">
        <h3 id="clomipramine">clomipramine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:2597" class="top-aligned cpic-clomipramine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-clomipramine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38;<br /><a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>Normal Metabolizer</dd><dt>CYP2D6:</dt><dd>Intermediate Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>N/A</dd><dt>CYP2D6:</dt><dd>1.0</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C19: Normal metabolism of tertiary amines</li><li>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects</li></ul></td>
                      <td>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
              
                
                  <tr id="#PA166104964" class="top-aligned dpwg-clomipramine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184528" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104964" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104964-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.</td>
                      <td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline clopidogrel">
        <h3 id="clopidogrel">clopidogrel</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:32968" class="top-aligned cpic-clopidogrel">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />NVI</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-clopidogrel-3-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity</td>
                      <td>If considering clopidogrel, use at standard dose (75 mg/day)</td>
                      <td>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.</td>
                      <td>Strong</td>
                  
                
                  <tr id="#RxNorm:32968" class="top-aligned cpic-clopidogrel">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />CVI non-ACS non-PCI</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-clopidogrel-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity</td>
                      <td>If considering clopidogrel, use at standard dose (75 mg/day)</td>
                      <td>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</td>
                      <td>Strong</td>
                  
                
                  <tr id="#RxNorm:32968" class="top-aligned cpic-clopidogrel">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />CVI ACS PCI </p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-clopidogrel-2-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity</td>
                      <td>If considering clopidogrel, use at standard dose (75 mg/day)</td>
                      <td>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104956" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21716271" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21716271</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23698643" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23698643</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35034351" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35034351</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline codeine">
        <h3 id="codeine">codeine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:2670" class="top-aligned cpic-codeine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-codeine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced morphine formation</td>
                      <td>Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104970" class="top-aligned dpwg-codeine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104970" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104970-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The genetic variation reduces the conversion of codeine to morphine. This can result in reduced analgesia.</td>
                      <td>For COUGH:
<ol>
<li>No action required.</li>
</ol>
For PAIN:
It is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.
<ol>
<li>Be alert to a reduced effectiveness.</li>
<li>In the case of inadequate effectiveness: 1. Try a dose increase., 2. If this does not work: choose an alternative.
Do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>
<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34267337" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34267337</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22205192" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:22205192</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24458010" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24458010</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/33387367" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:33387367</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline dapsone">
        <h3 id="dapsone">dapsone</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline desflurane">
        <h3 id="desflurane">desflurane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:27340" class="top-aligned cpic-desflurane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-desflurane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline desipramine">
        <h3 id="desipramine">desipramine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:3247" class="top-aligned cpic-desipramine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-desipramine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td>
                      <td>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline dexlansoprazole">
        <h3 id="dexlansoprazole">dexlansoprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:816346" class="top-aligned cpic-dexlansoprazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-dexlansoprazole-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs</td>
                      <td>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.</td>
                      <td>N/A</td>
                      <td>Optional</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32770672" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32770672</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline dimercaprol">
        <h3 id="dimercaprol">dimercaprol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline doxepin">
        <h3 id="doxepin">doxepin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:3638" class="top-aligned cpic-doxepin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-doxepin-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38;<br /><a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>Normal Metabolizer</dd><dt>CYP2D6:</dt><dd>Intermediate Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>N/A</dd><dt>CYP2D6:</dt><dd>1.0</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C19: Normal metabolism of tertiary amines</li><li>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects</li></ul></td>
                      <td>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104994" class="top-aligned dpwg-doxepin">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104994" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104994-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin.</td>
                      <td>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline doxorubicin">
        <h3 id="doxorubicin">doxorubicin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline efavirenz">
        <h3 id="efavirenz">efavirenz</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:195085" class="top-aligned cpic-efavirenz">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />child &gt;40kg_adult</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-efavirenz-1-1">
                            <span class="noWrap">
                              <a href="#CYP2B6">CYP2B6</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2B6: Normal efavirenz metabolism</td>
                      <td>Initiate efavirenz with standard dosing (600 mg/day)</td>
                      <td>The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype (PMID 24522178).</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166182846" class="top-aligned dpwg-efavirenz">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182846" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166182846-1">
                            <span class="noWrap">
                              <a href="#CYP2B6">CYP2B6</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2B6: The guideline does not provide a description of the impact of a normal metabolizer phenotype on efavirenz.</td>
                      <td>The guideline does not provide a recommendation for efavirenz in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31006110" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2019. PMID:31006110</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline eliglustat">
        <h3 id="eliglustat">eliglustat</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166182823" class="top-aligned dpwg-eliglustat">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182823" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166182823-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.</td>
                      <td><ul>
<li>Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR: Eliglustat is contra-indicated.</li>
</ul>
<ol>
<li>Choose an alternative if possible.
Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.</li>
</ol>
<ul>
<li>Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):</li>
</ul>
<ol>
<li>Use a dose of 84mg eliglustat 1x daily.</li>
</ol>
<ul>
<li>Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):</li>
</ul>
<ol>
<li>Consider a dose of 84mg eliglustat 1x daily.</li>
<li>Be alert to side effects.</li>
</ol>
<ul>
<li>Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):</li>
</ul>
<ol>
<li>Choose an alternative if possible.</li>
<li>If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.</li>
</ol>
<ul>
<li>Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):</li>
</ul>
<ol>
<li>Choose an alternative.</li>
<li>If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.</li>
</ol>
<ul>
<li>Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.</li>
</ul>
<ol>
<li>Choose an alternative if possible.</li>
</ol>
<ul>
<li>NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:</li>
</ul>
<ol>
<li>Use the standard dose of 84mg 2x daily.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline enflurane">
        <h3 id="enflurane">enflurane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:3920" class="top-aligned cpic-enflurane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-enflurane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline escitalopram">
        <h3 id="escitalopram">escitalopram</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:321988" class="top-aligned cpic-escitalopram">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-escitalopram-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104975" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34782755" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34782755</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25974703</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline flecainide">
        <h3 id="flecainide">flecainide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104969" class="top-aligned dpwg-flecainide">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104969" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104969-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects.</td>
                      <td><ol>
<li>Indications other than diagnosis of Brugada syndrome: reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.2.Provocation test for diagnosis of Brugada syndrome:No action required.At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity.All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline flucytosine">
        <h3 id="flucytosine">flucytosine</h3>

        
          <div class="alert alert-info DPYD-lowest-activity-score-note">The two lowest activity values (variant activity scores, see CPIC guideline PMID: 29152729) are used to determine the gene activity score and phenotype type to retrieve prescribing recommendations. </div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166222801" class="top-aligned dpwg-flucytosine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166222801" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166222801-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2</p>
                      
                    </td>
                  
                      <td>DPYD: The guideline does not provide a description of the impact of a DPYD activity score of 2 on flucytosine.</td>
                      <td>The guideline does not provide a recommendation for flucytosine in patients with a DPYD activity score of 2.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline fluorouracil">
        <h3 id="fluorouracil">fluorouracil</h3>

        
          <div class="alert alert-info DPYD-lowest-activity-score-note">The two lowest activity values (variant activity scores, see CPIC guideline PMID: 29152729) are used to determine the gene activity score and phenotype type to retrieve prescribing recommendations. </div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:4492" class="top-aligned cpic-fluorouracil">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-fluorouracil-1-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>DPYD: Normal DPD activity and "normal" risk for fluoropyrimidine toxicity</td>
                      <td>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104939" class="top-aligned dpwg-fluorouracil">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104939" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104939-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2</p>
                      
                    </td>
                  
                      <td>DPYD: The guideline does not provide a description of the impact of a DPYD activity score of 2 on fluorouracil.</td>
                      <td>The guideline does not provide a recommendation for fluorouracil in patients with a DPYD activity score of 2.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31745289" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.</a> <i>European journal of human genetics : EJHG</i>. 2019. PMID:31745289</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23988873" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23988873</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29152729" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2017. PMID:29152729</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline flurbiprofen">
        <h3 id="flurbiprofen">flurbiprofen</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:4502" class="top-aligned cpic-flurbiprofen">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-flurbiprofen-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline fluvastatin">
        <h3 id="fluvastatin">fluvastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:41127" class="top-aligned cpic-fluvastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-fluvastatin-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-fluvastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C9:</dt><dd>Normal Metabolizer</dd><dt>SLCO1B1:</dt><dd>Normal Function</dd></dl>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C9: Normal exposure.</li><li>SLCO1B1: Typical myopathy risk and statin exposure.</li></ul></td>
                      <td>Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline fluvoxamine">
        <h3 id="fluvoxamine">fluvoxamine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:42355" class="top-aligned cpic-fluvoxamine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-fluvoxamine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects.</td>
                      <td>Initiate therapy with recommended starting dose.</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25974703</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline fosphenytoin">
        <h3 id="fosphenytoin">fosphenytoin</h3>

        
          <div class="alert alert-info Phenytoin-HLA-B-warning">The displayed recommendation for CYP2C9 and phenytoin is ONLY valid for non-carriers of the HLA-B*15:02 high-risk allele. PharmCAT Named Allele Matcher does not determine HLA status. CPIC guidance: Fos-/Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of fos-/phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In HLA-B*15:02 carriers, carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele, and thus caution should be used in choosing alternatives to phenytoin.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:72236" class="top-aligned cpic-fosphenytoin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />PHT use &gt;3mos</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-fosphenytoin-2-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C9: Normal phenytoin metabolism</li><li>HLA-B: Increased risk of phenytoin-induced SJS/TEN</li></ul></td>
                      <td>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</td>
                      <td>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</td>
                      <td>Optional</td>
                  
                
                  <tr id="#RxNorm:72236" class="top-aligned cpic-fosphenytoin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />PHT naive</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-fosphenytoin-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C9: Normal phenytoin metabolism</li><li>HLA-B: Increased risk of phenytoin-induced SJS/TEN</li></ul></td>
                      <td>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</td>
                      <td>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25099164" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:25099164</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32779747" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32779747</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline furazolidone">
        <h3 id="furazolidone">furazolidone</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline gentamicin">
        <h3 id="gentamicin">gentamicin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#ATC:D06AX07" class="top-aligned cpic-gentamicin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-gentamicin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline glyburide">
        <h3 id="glyburide">glyburide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline haloperidol">
        <h3 id="haloperidol">haloperidol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104988" class="top-aligned dpwg-haloperidol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104988" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104988-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The genetic variation results in a higher plasma concentration, but the effect is small and no clinically significant effects were found.</td>
                      <td>NO action is required for this gene-drug interaction.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline halothane">
        <h3 id="halothane">halothane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:5095" class="top-aligned cpic-halothane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-halothane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline hydrocodone">
        <h3 id="hydrocodone">hydrocodone</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:5489" class="top-aligned cpic-hydrocodone">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-hydrocodone-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Minimal evidence for pharmacokinetic or clinical effect.</td>
                      <td>Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.</td>
                      <td>N/A</td>
                      <td>Optional</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22205192" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:22205192</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24458010" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24458010</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/33387367" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:33387367</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline hydroxychloroquine">
        <h3 id="hydroxychloroquine">hydroxychloroquine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline ibuprofen">
        <h3 id="ibuprofen">ibuprofen</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:5640" class="top-aligned cpic-ibuprofen">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-ibuprofen-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline imipramine">
        <h3 id="imipramine">imipramine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:5691" class="top-aligned cpic-imipramine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-imipramine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38;<br /><a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>Normal Metabolizer</dd><dt>CYP2D6:</dt><dd>Intermediate Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>N/A</dd><dt>CYP2D6:</dt><dd>1.0</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C19: Normal metabolism of tertiary amines</li><li>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects</li></ul></td>
                      <td>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
              
                
                  <tr id="#PA166104972" class="top-aligned dpwg-imipramine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104954" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104972" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104972-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine.</td>
                      <td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline irinotecan">
        <h3 id="irinotecan">irinotecan</h3>

        
          <div class="alert alert-info irinotecan-DPWG">Alleles determined based on the CPIC UGT1A1 allele definition file due to limited allele definition information in the DPWG UGT1A1 document</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104951" class="top-aligned dpwg-irinotecan">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104951" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104951-1">
                            <span class="noWrap">
                              <a href="#UGT1A1">UGT1A1</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>UGT1A1: The guideline does not provide a description of the impact of a normal metabolizer phenotype on irinotecan.</td>
                      <td>The guideline does not provide a recommendation for irinotecan in normal metabolizers</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline isoflurane">
        <h3 id="isoflurane">isoflurane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:6026" class="top-aligned cpic-isoflurane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-isoflurane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline ivacaftor">
        <h3 id="ivacaftor">ivacaftor</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:1243041" class="top-aligned cpic-ivacaftor">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-ivacaftor-1-1">
                            <span class="noWrap">
                              <a href="#CFTR">CFTR</a>:<br />No CPIC variants found
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>ivacaftor non-responsive in CF patients</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CFTR: An individual diagnosed with cystic fibrosis (CF) and negative for a CFTR variant listed in the FDA-approved drug label as being responsive to ivacaftor.</td>
                      <td>Ivacaftor is not recommended</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24598717" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24598717</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline kanamycin">
        <h3 id="kanamycin">kanamycin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:6099" class="top-aligned cpic-kanamycin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-kanamycin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline lansoprazole">
        <h3 id="lansoprazole">lansoprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:17128" class="top-aligned cpic-lansoprazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-lansoprazole-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs</td>
                      <td>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104987" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32770672" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32770672</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline lornoxicam">
        <h3 id="lornoxicam">lornoxicam</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:20890" class="top-aligned cpic-lornoxicam">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-lornoxicam-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline lovastatin">
        <h3 id="lovastatin">lovastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:6472" class="top-aligned cpic-lovastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />population general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-lovastatin-1-1">
                            <span class="noWrap">
                              <a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-lovastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Function</p>
                      
                      
                    </td>
                  
                      <td>SLCO1B1: Typical myopathy risk and statin exposure</td>
                      <td>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline mafenide">
        <h3 id="mafenide">mafenide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline meloxicam">
        <h3 id="meloxicam">meloxicam</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:41493" class="top-aligned cpic-meloxicam">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-meloxicam-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline mercaptopurine">
        <h3 id="mercaptopurine">mercaptopurine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:103" class="top-aligned cpic-mercaptopurine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-mercaptopurine-1-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1;<br /><a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>Normal Metabolizer</dd><dt>TPMT:</dt><dd>Normal Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>N/A</dd><dt>TPMT:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</li><li>TPMT: Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</li></ul></td>
                      <td>Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).</td>
                      <td>Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166184613" class="top-aligned dpwg-mercaptopurine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184613" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104952" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166184613-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>NUDT15: The guideline does not provide a description of the impact of a normal metabolizer phenotype on mercaptopurine.</td>
                      <td>The guideline does not provide a recommendation for mercaptopurine in normal metabolizers</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
                
                  <tr id="#PA166104952" class="top-aligned dpwg-mercaptopurine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184613" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104952" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104952-1">
                            <span class="noWrap">
                              <a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>TPMT: The guideline does not provide a description of the impact of a normal metabolizer phenotype on mercaptopurine.</td>
                      <td>The guideline does not provide a recommendation for mercaptopurine in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794" target="_blank" rel="noopener noreferrer">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21270794</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23422873</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30447069" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30447069</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline methoxyflurane">
        <h3 id="methoxyflurane">methoxyflurane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:6857" class="top-aligned cpic-methoxyflurane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-methoxyflurane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline methylene blue">
        <h3 id="methylene blue">methylene blue</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline metoprolol">
        <h3 id="metoprolol">metoprolol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104995" class="top-aligned dpwg-metoprolol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104995" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104995-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.</td>
                      <td>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose. OTHER CASES: 1. no action required</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline nalidixic acid">
        <h3 id="nalidixic acid">nalidixic acid</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline nitrofurantoin">
        <h3 id="nitrofurantoin">nitrofurantoin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline norfloxacin">
        <h3 id="norfloxacin">norfloxacin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline nortriptyline">
        <h3 id="nortriptyline">nortriptyline</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:7531" class="top-aligned cpic-nortriptyline">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-nortriptyline-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td>
                      <td>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104961" class="top-aligned dpwg-nortriptyline">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104961" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104961-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects may be increased, because the gene variation leads to an increased plasma concentration of nortriptyline.</td>
                      <td>Use 60% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.
The therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline ofloxacin">
        <h3 id="ofloxacin">ofloxacin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline omeprazole">
        <h3 id="omeprazole">omeprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:7646" class="top-aligned cpic-omeprazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-omeprazole-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs</td>
                      <td>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104957" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32770672" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32770672</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline ondansetron">
        <h3 id="ondansetron">ondansetron</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:26225" class="top-aligned cpic-ondansetron">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-ondansetron-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers</td>
                      <td>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</td>
                      <td>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</td>
                      <td>No Recommendation</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28002639" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:28002639</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline oxcarbazepine">
        <h3 id="oxcarbazepine">oxcarbazepine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:32624" class="top-aligned cpic-oxcarbazepine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />OXC use &gt;3 mos</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-oxcarbazepine-2-1">
                            <span class="noWrap">
                              <a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN</td>
                      <td>The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.</td>
                      <td>Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</td>
                      <td>Optional</td>
                  
                
                  <tr id="#RxNorm:32624" class="top-aligned cpic-oxcarbazepine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />OXC naive</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-oxcarbazepine-1-1">
                            <span class="noWrap">
                              <a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN</td>
                      <td>If patient is oxcarbazepine-naïve, do not use oxcarbazepine.</td>
                      <td>Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23695185" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23695185</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29392710" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:29392710</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline pantoprazole">
        <h3 id="pantoprazole">pantoprazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:40790" class="top-aligned cpic-pantoprazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-pantoprazole-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs</td>
                      <td>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104958" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32770672" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32770672</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline paromomycin">
        <h3 id="paromomycin">paromomycin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:7934" class="top-aligned cpic-paromomycin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-paromomycin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline paroxetine">
        <h3 id="paroxetine">paroxetine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:32937" class="top-aligned cpic-paroxetine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-paroxetine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects.</td>
                      <td>Initiate therapy with recommended starting dose</td>
                      <td>N/A</td>
                      <td>Moderate</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104976" class="top-aligned dpwg-paroxetine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104976" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104976-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.</td>
                      <td>NO action is needed for this gene-drug interaction.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34782755" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34782755</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25974703</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline peginterferon alfa-2a">
        <h3 id="peginterferon alfa-2a">peginterferon alfa-2a</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#IFNL3/4">IFNL3/4</a> rs12979860 reference (C)/rs12979860 reference (C).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24096968" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:24096968</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline peginterferon alfa-2b">
        <h3 id="peginterferon alfa-2b">peginterferon alfa-2b</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#IFNL3/4">IFNL3/4</a> rs12979860 reference (C)/rs12979860 reference (C).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24096968" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:24096968</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline pegloticase">
        <h3 id="pegloticase">pegloticase</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline phenazopyridine">
        <h3 id="phenazopyridine">phenazopyridine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline phenprocoumon">
        <h3 id="phenprocoumon">phenprocoumon</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104940" class="top-aligned dpwg-phenprocoumon">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104940" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104940-1">
                            <span class="noWrap">
                              <a href="#VKORC1">VKORC1</a>:<br />rs9923231 reference (C)/<br />rs9923231 reference (C)
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>VKORC1: The guideline does not provide a description of the impact of the VKORC1 rs9923231 CC genotype (-1639 GG genotype) on phenprocoumon.</td>
                      <td>The guideline does not provide a recommendation for phenprocoumon in patients with the VKORC1 rs9923231 CC genotype (-1639 GG genotype).</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline phenytoin">
        <h3 id="phenytoin">phenytoin</h3>

        
          <div class="alert alert-info Phenytoin-HLA-B-warning">The displayed recommendation for CYP2C9 and phenytoin is ONLY valid for non-carriers of the HLA-B*15:02 high-risk allele. PharmCAT Named Allele Matcher does not determine HLA status. CPIC guidance: Fos-/Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of fos-/phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In HLA-B*15:02 carriers, carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele, and thus caution should be used in choosing alternatives to phenytoin.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:8183" class="top-aligned cpic-phenytoin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />PHT naive</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-phenytoin-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C9: Normal phenytoin metabolism</li><li>HLA-B: Increased risk of phenytoin-induced SJS/TEN</li></ul></td>
                      <td>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.</td>
                      <td>Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.</td>
                      <td>Strong</td>
                  
                
                  <tr id="#RxNorm:8183" class="top-aligned cpic-phenytoin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />PHT use &gt;3mos</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-phenytoin-2-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#HLA-B">HLA-B</a>:*15:02/*57:01
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C9: Normal phenytoin metabolism</li><li>HLA-B: Increased risk of phenytoin-induced SJS/TEN</li></ul></td>
                      <td>If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.</td>
                      <td>Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104984" class="top-aligned dpwg-phenytoin">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104984" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104984-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C9: The guideline does not provide a description of the impact of a normal metabolizer phenotype on phenytoin.</td>
                      <td>The guideline does not provide a recommendation for phenytoin in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25099164" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:25099164</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32779747" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32779747</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline pimozide">
        <h3 id="pimozide">pimozide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166182819" class="top-aligned dpwg-pimozide">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182819" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166182819-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The elevated plasma concentration and associated theoretical increased risk of QT elongation can be negated by following the dose recommendations provided below.</td>
                      <td>Use no more than the following doses (80% of the standard maximum dose):
12 years and older: 16 mg/day
younger than 12 years: 0.08 mg/kg per day to a maximum of 3 mg/day</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline piroxicam">
        <h3 id="piroxicam">piroxicam</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:8356" class="top-aligned cpic-piroxicam">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-piroxicam-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline pitavastatin">
        <h3 id="pitavastatin">pitavastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:861634" class="top-aligned cpic-pitavastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />population general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-pitavastatin-1-1">
                            <span class="noWrap">
                              <a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-pitavastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Function</p>
                      
                      
                    </td>
                  
                      <td>SLCO1B1: Typical myopathy risk and statin exposure</td>
                      <td>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline plazomicin">
        <h3 id="plazomicin">plazomicin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:2049549" class="top-aligned cpic-plazomicin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-plazomicin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline pravastatin">
        <h3 id="pravastatin">pravastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:42463" class="top-aligned cpic-pravastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />population general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-pravastatin-1-1">
                            <span class="noWrap">
                              <a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-pravastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Function</p>
                      
                      
                    </td>
                  
                      <td>SLCO1B1: Typical myopathy risk and statin exposure</td>
                      <td>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline primaquine">
        <h3 id="primaquine">primaquine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline propafenone">
        <h3 id="propafenone">propafenone</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104962" class="top-aligned dpwg-propafenone">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104962" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104962-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.</td>
                      <td>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.
<ol>
<li>Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects</li>
<li>Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline quetiapine">
        <h3 id="quetiapine">quetiapine</h3>

        
          <div class="alert alert-info CYP3A4">The CYP3A4 alleles are determined based on PharmVar CYP3A4 allele definitions. See PharmCAT disclaimer for further information.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166265421" class="top-aligned dpwg-quetiapine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166265421" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166265421-1">
                            <span class="noWrap">
                              <a href="#CYP3A4">CYP3A4</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP3A4: The guideline does not provide a description of the impact of a normal metabolizer phenotype on quetiapine.</td>
                      <td>The guideline does not provide a recommendation for quetiapine in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline quinine">
        <h3 id="quinine">quinine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline rasburicase">
        <h3 id="rasburicase">rasburicase</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline risperidone">
        <h3 id="risperidone">risperidone</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104943" class="top-aligned dpwg-risperidone">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104943" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104943-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.</td>
                      <td>NO action is needed for this gene-drug interaction.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline rosuvastatin">
        <h3 id="rosuvastatin">rosuvastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:301542" class="top-aligned cpic-rosuvastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-rosuvastatin-1-1">
                            <span class="noWrap">
                              <a href="#ABCG2">ABCG2</a>:<br />rs2231142 reference (G)/<br />rs2231142 reference (G);<br /><a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-rosuvastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>ABCG2:</dt><dd>Normal Function</dd><dt>SLCO1B1:</dt><dd>Normal Function</dd></dl>
                      
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>ABCG2: Typical myopathy risk and rosuvastatin exposure</li><li>SLCO1B1: Typical myopathy risk and statin exposure</li></ul></td>
                      <td>Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sertraline">
        <h3 id="sertraline">sertraline</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:36437" class="top-aligned cpic-sertraline">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-sertraline-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP2C19: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104980" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34782755" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34782755</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25974703</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sevoflurane">
        <h3 id="sevoflurane">sevoflurane</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:36453" class="top-aligned cpic-sevoflurane">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-sevoflurane-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline simvastatin">
        <h3 id="simvastatin">simvastatin</h3>

        
          <div class="alert alert-info SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:36567" class="top-aligned cpic-simvastatin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-statins/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-simvastatin-1-1">
                            <span class="noWrap">
                              <a href="#SLCO1B1">SLCO1B1</a>:*1/*1;<br /><span id="cpic-simvastatin-1-1-rs4149056">rs4149056:T/T</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Function</p>
                      
                      
                    </td>
                  
                      <td>SLCO1B1: Typical myopathy risk and statin exposure</td>
                      <td>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</td>
                      <td>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182844" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#SLCO1B1">SLCO1B1</a> *1/*1.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a>. <i>Clinical pharmacology and therapeutics</i>. 2012. PMID:22617227</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24918167</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/35152405" target="_blank" rel="noopener noreferrer">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:35152405</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline siponimod">
        <h3 id="siponimod">siponimod</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166211021" class="top-aligned dpwg-siponimod">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166211021" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166211021-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C9: The guideline does not provide a description of the impact of a normal metabolizer phenotype on siponimod.</td>
                      <td>The guideline does not provide a recommendation for siponimod in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
      </section>
    
      <section class="guideline streptomycin">
        <h3 id="streptomycin">streptomycin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10109" class="top-aligned cpic-streptomycin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-streptomycin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline succinylcholine">
        <h3 id="succinylcholine">succinylcholine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10154" class="top-aligned cpic-succinylcholine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-succinylcholine-1-1">
                            <span class="noWrap">
                              <a href="#CACNA1S">CACNA1S</a>:Reference/<br />Reference;<br /><a href="#RYR1">RYR1</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>Uncertain Susceptibility</dd><dt>RYR1:</dt><dd>Uncertain Susceptibility</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CACNA1S:</dt><dd>N/A</dd><dt>RYR1:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CACNA1S: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li><li>RYR1: These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).</li></ul></td>
                      <td>Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30499100" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes</a>. <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30499100</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfadiazine">
        <h3 id="sulfadiazine">sulfadiazine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfadimidine">
        <h3 id="sulfadimidine">sulfadimidine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfamethoxazole / trimethoprim">
        <h3 id="sulfamethoxazole / trimethoprim">sulfamethoxazole / trimethoprim</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfanilamide">
        <h3 id="sulfanilamide">sulfanilamide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfasalazine">
        <h3 id="sulfasalazine">sulfasalazine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline sulfisoxazole">
        <h3 id="sulfisoxazole">sulfisoxazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tacrolimus">
        <h3 id="tacrolimus">tacrolimus</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:42316" class="top-aligned cpic-tacrolimus">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tacrolimus-1-1">
                            <span class="noWrap">
                              <a href="#CYP3A5">CYP3A5</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>N/A</p>
                      
                    </td>
                  
                      <td>CYP3A5: Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.</td>
                      <td>Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104983" class="top-aligned dpwg-tacrolimus">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104983" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104983-1">
                            <span class="noWrap">
                              <a href="#CYP3A5">CYP3A5</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>CYP3A5: An increase of the initial dose can result in an increased chance of reaching a tacrolimus concentration within the target range before the start of therapeutic drug monitoring. However, there is no direct evidence that this results in improved clinical results. The genetic variation results in an increased conversion of tacrolimus to inactive metabolites and therefore a higher required dose.</td>
                      <td>LIVER TRANSPLANTATION
In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.
LIVER is also of the genotype HOMOZYGOUS EXPRESSOR: Use 2.5 times the normal initial dose. Adjustment of the dose should then be based on therapeutic drug monitoring.
LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation.
OTHER TRANSPLANTATION
Use 2.5 times the initial dose that would yield the desired result in non-expressers. Adjustment of the dose should then be based on therapeutic drug monitoring. For example: One Dutch study found a median trough concentration for tacrolimus after three days of 9.4 ng/mL at an initial dose of 0.15 mg/kg twice daily for 5 homozygous kidney transplant patients. Their target value was 10 - 15 ng/mL.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25801146" target="_blank" rel="noopener noreferrer">Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2015. PMID:25801146</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tafenoquine">
        <h3 id="tafenoquine">tafenoquine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tamoxifen">
        <h3 id="tamoxifen">tamoxifen</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10324" class="top-aligned cpic-tamoxifen">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tamoxifen-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.</td>
                      <td>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</td>
                      <td>N/A</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104966" class="top-aligned dpwg-tamoxifen">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104966" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104966-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.</td>
                      <td><ol>
<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>
<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29385237" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:29385237</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tegafur">
        <h3 id="tegafur">tegafur</h3>

        
          <div class="alert alert-info DPYD-lowest-activity-score-note">The two lowest activity values (variant activity scores, see CPIC guideline PMID: 29152729) are used to determine the gene activity score and phenotype type to retrieve prescribing recommendations. </div>
        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104944" class="top-aligned dpwg-tegafur">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104944" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104944-1">
                            <span class="noWrap">
                              <a href="#DPYD">DPYD</a>:Reference/<br />Reference
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2</p>
                      
                    </td>
                  
                      <td>DPYD: The guideline does not provide a description of the impact of a DPYD activity score of 2 on tegafur.</td>
                      <td>The guideline does not provide a recommendation for tegafur in patients with a DPYD activity score of 2.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31745289" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.</a> <i>European journal of human genetics : EJHG</i>. 2019. PMID:31745289</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tenoxicam">
        <h3 id="tenoxicam">tenoxicam</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:37790" class="top-aligned cpic-tenoxicam">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tenoxicam-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>2.0</p>
                      
                    </td>
                  
                      <td>CYP2C9: Normal metabolism</td>
                      <td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                      <td>N/A</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32189324" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.</a> <i>Clinical pharmacology and therapeutics</i>. 2020. PMID:32189324</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline thioguanine">
        <h3 id="thioguanine">thioguanine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10485" class="top-aligned cpic-thioguanine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-thioguanine-1-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1;<br /><a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>Normal Metabolizer</dd><dt>TPMT:</dt><dd>Normal Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>NUDT15:</dt><dd>N/A</dd><dt>TPMT:</dt><dd>N/A</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>NUDT15: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</li><li>TPMT: Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</li></ul></td>
                      <td>Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).</td>
                      <td>Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166184612" class="top-aligned dpwg-thioguanine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184612" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104960" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166184612-1">
                            <span class="noWrap">
                              <a href="#NUDT15">NUDT15</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>NUDT15: The guideline does not provide a description of the impact of a normal metabolizer phenotype on thioguanine.</td>
                      <td>The guideline does not provide a recommendation for thioguanine in normal metabolizers</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
                
                  <tr id="#PA166104960" class="top-aligned dpwg-thioguanine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166184612" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104960" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104960-1">
                            <span class="noWrap">
                              <a href="#TPMT">TPMT</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>TPMT: The guideline does not provide a description of the impact of a normal metabolizer phenotype on thioguanine.</td>
                      <td>The guideline does not provide a recommendation for thioguanine in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794" target="_blank" rel="noopener noreferrer">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21270794</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23422873</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/30447069" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.</a> <i>Clinical pharmacology and therapeutics</i>. 2018. PMID:30447069</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tobramycin">
        <h3 id="tobramycin">tobramycin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10627" class="top-aligned cpic-tobramycin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tobramycin-1-1">
                            <span class="noWrap">
                              <a href="#MT-RNR1">MT-RNR1</a>:1555A>G
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>increased risk of aminoglycoside-induced hearing loss</p>
                      
                      
                    </td>
                  
                      <td>MT-RNR1: Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.</td>
                      <td>Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.</td>
                      <td>If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).</td>
                      <td>Strong</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34032273" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:34032273</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tolbutamide">
        <h3 id="tolbutamide">tolbutamide</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline toluidine blue">
        <h3 id="toluidine blue">toluidine blue</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tramadol">
        <h3 id="tramadol">tramadol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10689" class="top-aligned cpic-tramadol">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tramadol-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Reduced O-desmethyltramadol (active metabolite) formation</td>
                      <td>Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.</td>
                      <td>N/A</td>
                      <td>Optional</td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166104959" class="top-aligned dpwg-tramadol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104959" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104959-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia.</td>
                      <td>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.
<ol>
<li>be alert to a reduced effectiveness</li>
<li>in the case of inadequate effectiveness:
a. try a dose increase
b. if this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>
<li>if no alternative is selected: advise the patient to report inadequate analgesia</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/34267337" target="_blank" rel="noopener noreferrer">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).</a> <i>European journal of human genetics : EJHG</i>. 2021. PMID:34267337</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22205192" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:22205192</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24458010" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2014. PMID:24458010</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/33387367" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.</a> <i>Clinical pharmacology and therapeutics</i>. 2021. PMID:33387367</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline trimipramine">
        <h3 id="trimipramine">trimipramine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:10834" class="top-aligned cpic-trimipramine">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-trimipramine-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38;<br /><a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotypes</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>Normal Metabolizer</dd><dt>CYP2D6:</dt><dd>Intermediate Metabolizer</dd></dl>
                      
                      
                        <div class="hint">Activity Scores</div>
                        <dl class="compact mt-0"><dt>CYP2C19:</dt><dd>N/A</dd><dt>CYP2D6:</dt><dd>1.0</dd></dl>
                      
                    </td>
                  
                      <td><ul class="noPadding mt-0"><li>CYP2C19: Normal metabolism of tertiary amines</li><li>CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects</li></ul></td>
                      <td>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                      <td>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</td>
                      <td>Optional</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27997040</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a>. <i>Clinical pharmacology and therapeutics</i>. 2013. PMID:23486447</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline tropisetron">
        <h3 id="tropisetron">tropisetron</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:27392" class="top-aligned cpic-tropisetron">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />general</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-tropisetron-1-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>1.0</p>
                      
                    </td>
                  
                      <td>CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers</td>
                      <td>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</td>
                      <td>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</td>
                      <td>No Recommendation</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28002639" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:28002639</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline venlafaxine">
        <h3 id="venlafaxine">venlafaxine</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104968" class="top-aligned dpwg-venlafaxine">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104968" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104968-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found.</td>
                      <td>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.
<ul>
<li>avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>
<li>if it is not possible to avoid venlafaxine and side effects occur:</li>
</ul>
<ol>
<li>reduce the dose</li>
<li>monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.
It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</li>
</ol></td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline vitamin c">
        <h3 id="vitamin c">vitamin c</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline vitamin k">
        <h3 id="vitamin k">vitamin k</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>CPIC</b>
                    
                      <sup class="sources">
                        <a href="https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#G6PD">G6PD</a> B (wildtype)/B (wildtype).
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/36049896" target="_blank" rel="noopener noreferrer">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.</a> <i>Clinical pharmacology and therapeutics</i>. 2022. PMID:36049896</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline voriconazole">
        <h3 id="voriconazole">voriconazole</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:121243" class="top-aligned cpic-voriconazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />adults</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-voriconazole-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C19: Normal voriconazole metabolism</td>
                      <td>Initiate therapy with recommended standard of care dosing</td>
                      <td>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</td>
                      <td>Strong</td>
                  
                
                  <tr id="#RxNorm:121243" class="top-aligned cpic-voriconazole">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />pediatrics</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="cpic-voriconazole-2-1">
                            <span class="noWrap">
                              <a href="#CYP2C19">CYP2C19</a>:*38/*38
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C19: Normal voriconazole metabolism</td>
                      <td>Initiate therapy with recommended standard of care dosing</td>
                      <td>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</td>
                      <td>Strong</td>
                  
                
              
            
          
            
              <tr>
                <td class="top-aligned">
                  <p>
                    <b>PharmGKB-DPWG</b>
                    
                      <sup class="sources">
                        <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104990" target="_blank" rel="noopener noreferrer">1</a>
                      </sup>
                    
                  </p>
                </td>
                <td colspan="5" class="top-aligned">
                  
                    No annotation for <a href="#CYP2C19">CYP2C19</a> *38/*38.
                  
                </td>
              </tr>
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27981572" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy</a>. <i>Clinical pharmacology and therapeutics</i>. 2016. PMID:27981572</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline warfarin">
        <h3 id="warfarin">warfarin</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#RxNorm:11289" class="top-aligned cpic-warfarin">
                    <td>
                      <p>
                        <b>CPIC</b>
                        
                          <sup class="sources">
                            <a href="https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="warfarin-cpic-1-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1;<br /><a href="#CYP4F2">CYP4F2</a>:*1/*1;<br /><a href="#VKORC1">VKORC1</a>:<br />rs9923231 reference (C)/<br />rs9923231 reference (C);<br /><span id="warfarin-cpic-1-1-rs12777823">rs12777823:G/G</span>
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td colspan="4">
                        
                          <div class="alert alert-info pcat-cpic-warfarin-1-flowchart">Please follow the flow chart in figure 2 of the <a href="https://www.pharmgkb.org/guideline/PA166104949">CPIC warfarin guideline</a> to determine the appropriate dosing recommendation.</div>
                        
                          <div class="alert alert-info pcat-cpic-warfarin-2-vkorc1">The CPIC warfarin guideline only considers a single SNV in VKORC1 (rs9923231), which has varying frequency among different ancestral populations, and largely explains the differences in average dose requirements between people of European, African, and Asian descents. While other functional variants in VKORC1 have been associated with warfarin resistance (high dose requirements), there are currently no CPIC recommendations for how to use these other variants in warfarin dosing. An alternate name for rs9923231 is -1639G>A (note that VKORC1 is on the negative chromosomal strand, so displayed alleles are complemented). </div>
                        
                        <div class="warfarinFlowchart">
                          <img src="https://files.cpicpgx.org/images/warfarin/warfarin_recommendation_diagram.png"
                              alt="Figure 2 from the CPIC guideline for warfarin"/>
                        </div>
                      </td>
                  
                
              
            
          
            
              
                
                  <tr id="#PA166182842" class="top-aligned dpwg-warfarin">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182842" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182841" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166182842-1">
                            <span class="noWrap">
                              <a href="#CYP2C9">CYP2C9</a>:*1/*1
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Normal Metabolizer</p>
                      
                      
                    </td>
                  
                      <td>CYP2C9: The guideline does not provide a description of the impact of a normal metabolizer phenotype on warfarin.</td>
                      <td>The guideline does not provide a recommendation for warfarin in normal metabolizers.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
                
                  <tr id="#PA166182841" class="top-aligned dpwg-warfarin">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182842" target="_blank" rel="noopener noreferrer">1</a>, <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166182841" target="_blank" rel="noopener noreferrer">2</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166182841-1">
                            <span class="noWrap">
                              <a href="#VKORC1">VKORC1</a>:<br />rs9923231 reference (C)/<br />rs9923231 reference (C)
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                      
                    </td>
                  
                      <td>VKORC1: The guideline does not provide a description of the impact of the VKORC1 rs9923231 CC genotype (-1639 GG genotype) on warfarin.</td>
                      <td>The guideline does not provide a recommendation for warfarin in patients with the VKORC1 rs9923231 CC genotype (-1639 GG genotype).</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21900891" target="_blank" rel="noopener noreferrer">Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing</a>. <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21900891</li>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28198005" target="_blank" rel="noopener noreferrer">Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update</a>. <i>Clinical pharmacology and therapeutics</i>. 2017. PMID:28198005</li>
              
            </ul>
          </div>
        
      </section>
    
      <section class="guideline zuclopenthixol">
        <h3 id="zuclopenthixol">zuclopenthixol</h3>

        

        <table>
          <thead>
          <tr>
            <th>Guideline</th>
            <th>Genes</th>
            <th>Implications</th>
            <th>Recommendation</th>
            <th>Comments</th>
            <th>Classification</th>
          </tr>
          </thead>
          <tbody>
          
            
              
                
                  <tr id="#PA166104992" class="top-aligned dpwg-zuclopenthixol">
                    <td>
                      <p>
                        <b>PharmGKB-DPWG</b>
                        
                          <sup class="sources">
                            <a href="https://www.pharmgkb.org/guidelineAnnotation/PA166104992" target="_blank" rel="noopener noreferrer">1</a>
                          </sup>
                        
                      </p>
                      <p>Population:<br />N/A</p>
                    </td>
                    <td>
                      <div class="hint">Genotype</div>
                      <ul class="noBullet mt-0">
                        
                          <li id="dpwg-PA166104992-1">
                            <span class="noWrap">
                              <a href="#CYP2D6">CYP2D6</a>:*1/*3
                              
                              
                            </span>
                          </li>
                        
                      </ul>
                      
                        <div class="hint">Phenotype</div>
                        <p>Intermediate Metabolizer</p>
                      
                      
                        <div class="hint">Activity Score</div>
                        <p>0.5-1</p>
                      
                    </td>
                  
                      <td>CYP2D6: The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher.</td>
                      <td>Use 75% of the standard dose.</td>
                      <td>N/A</td>
                      <td>N/A</td>
                  
                
              
            
          
          </tbody>
        </table>

        
        

        

        
          <div class="citations">
            <p>Citations:</p>
            <ul>
              
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21412232" target="_blank" rel="noopener noreferrer">Pharmacogenetics: from bench to byte--an update of guidelines.</a> <i>Clinical pharmacology and therapeutics</i>. 2011. PMID:21412232</li>
              
            </ul>
          </div>
        
      </section>
    
  </section>


  <section id="section-iii">
    <h2>Section III: Allele Matching Details</h2>

    <ol>
      
        <li><a href="#ABCG2">ABCG2 allele match data</a></li>
      
        <li><a href="#CACNA1S">CACNA1S allele match data</a></li>
      
        <li><a href="#CFTR">CFTR allele match data</a></li>
      
        <li><a href="#CYP2B6">CYP2B6 allele match data</a></li>
      
        <li><a href="#CYP2C19">CYP2C19 allele match data</a></li>
      
        <li><a href="#CYP2C9">CYP2C9 allele match data</a></li>
      
        <li><a href="#CYP2D6">CYP2D6 allele match data</a></li>
      
        <li><a href="#CYP3A4">CYP3A4 allele match data</a></li>
      
        <li><a href="#CYP3A5">CYP3A5 allele match data</a></li>
      
        <li><a href="#CYP4F2">CYP4F2 allele match data</a></li>
      
        <li><a href="#DPYD">DPYD allele match data</a></li>
      
        <li><a href="#G6PD">G6PD allele match data</a></li>
      
        <li><a href="#HLA-B">HLA-B allele match data</a></li>
      
        <li><a href="#IFNL3/4">IFNL3/4 allele match data</a></li>
      
        <li><a href="#MT-RNR1">MT-RNR1 allele match data</a></li>
      
        <li><a href="#NUDT15">NUDT15 allele match data</a></li>
      
        <li><a href="#RYR1">RYR1 allele match data</a></li>
      
        <li><a href="#SLCO1B1">SLCO1B1 allele match data</a></li>
      
        <li><a href="#TPMT">TPMT allele match data</a></li>
      
        <li><a href="#UGT1A1">UGT1A1 allele match data</a></li>
      
        <li><a href="#VKORC1">VKORC1 allele match data</a></li>
      
    </ol>
    
      <p class="noGeneData">No data provided for <span class="gene f5"><span class="no-data">F5</span></span>, <span class="gene hla-a"><span class="no-data">HLA-A</span></span>.</p>
    


    
      <section class="gene ABCG2">
        <h3 id="ABCG2">ABCG2 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  rs2231142 reference (G)/rs2231142 reference (G)
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr4_88131171">chr4:88131171</td>
                  <td id="rs2231142">rs2231142</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    rs2231142 variant (T) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CACNA1S">
        <h3 id="CACNA1S">CACNA1S allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  Reference/Reference
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CACNA1S Reference allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr1_201060815">chr1:201060815</td>
                  <td id="rs1800559">rs1800559</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.3257G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_201091993">chr1:201091993</td>
                  <td id="rs772226819">rs772226819</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.520C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CFTR">
        <h3 id="CFTR">CFTR allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  No CPIC variants found
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr7_117509035">chr7:117509035</td>
                  <td id="rs397508256">rs397508256</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    E56K 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117509069">chr7:117509069</td>
                  <td id="rs368505753">rs368505753</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    P67L 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117509089">chr7:117509089</td>
                  <td id="rs115545701">rs115545701</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    R74W 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117530953">chr7:117530953</td>
                  <td id="rs113993958">rs113993958</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    D110H 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117530955">chr7:117530955</td>
                  <td id="rs397508537">rs397508537</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    D110E 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117530974">chr7:117530974</td>
                  <td id="rs77834169">rs77834169</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    R117C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117530975">chr7:117530975</td>
                  <td id="rs78655421">rs78655421</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    R117H 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117534318">chr7:117534318</td>
                  <td id="rs80282562">rs80282562</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G178R 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117534363">chr7:117534363</td>
                  <td id="rs397508759">rs397508759</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    E193K 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117534368">chr7:117534368</td>
                  <td id="rs397508761">rs397508761</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    711+3A-&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117535285">chr7:117535285</td>
                  <td id="rs121908752">rs121908752</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    L206W 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117540270">chr7:117540270</td>
                  <td id="rs77932196">rs77932196</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    R347H 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117540285">chr7:117540285</td>
                  <td id="rs121908753">rs121908753</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    R352Q 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117548795">chr7:117548795</td>
                  <td id="rs74551128">rs74551128</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    A455E 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117587799">chr7:117587799</td>
                  <td id="rs121908757">rs121908757</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    S549R(A&gt;C) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117587800">chr7:117587800</td>
                  <td id="rs121908755">rs121908755</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    S549N 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117587801">chr7:117587801</td>
                  <td id="rs121909005">rs121909005</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    S549R(T&gt;G) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117587805">chr7:117587805</td>
                  <td id="rs121909013">rs121909013</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G551S 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117587806">chr7:117587806</td>
                  <td id="rs75527207">rs75527207</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G551D 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117590409">chr7:117590409</td>
                  <td id="rs397508288">rs397508288</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    D579G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117594930">chr7:117594930</td>
                  <td id="rs397508387">rs397508387</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    E831X 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117602868">chr7:117602868</td>
                  <td id="rs80224560">rs80224560</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    2789+5G-&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117603708">chr7:117603708</td>
                  <td id="rs397508442">rs397508442</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    S945L 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117606695">chr7:117606695</td>
                  <td id="rs141033578">rs141033578</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    S977F 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611555">chr7:117611555</td>
                  <td id="rs76151804">rs76151804</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    3272-26A-&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611595">chr7:117611595</td>
                  <td id="rs150212784">rs150212784</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    F1052V 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611620">chr7:117611620</td>
                  <td id="rs397508513">rs397508513</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    K1060T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611640">chr7:117611640</td>
                  <td id="rs121909020">rs121909020</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    A1067T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611646">chr7:117611646</td>
                  <td id="rs200321110">rs200321110</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G1069R 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611649">chr7:117611649</td>
                  <td id="rs202179988">rs202179988</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    R1070W 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611650">chr7:117611650</td>
                  <td id="rs78769542">rs78769542</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    R1070Q 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117611663">chr7:117611663</td>
                  <td id="rs186045772">rs186045772</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    F1074L 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117614699">chr7:117614699</td>
                  <td id="rs75541969">rs75541969</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    D1152H 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117639961">chr7:117639961</td>
                  <td id="rs75039782">rs75039782</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    3849+10kbC-&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117642451">chr7:117642451</td>
                  <td id="rs267606723">rs267606723</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G1244E 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117642472">chr7:117642472</td>
                  <td id="rs74503330">rs74503330</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    S1251N 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117642483">chr7:117642483</td>
                  <td id="rs121909041">rs121909041</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    S1255P 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117642528">chr7:117642528</td>
                  <td id="rs11971167">rs11971167</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    D1270N 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_117664770">chr7:117664770</td>
                  <td id="rs193922525">rs193922525</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    G1349D 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CYP2B6">
        <h3 id="CYP2B6">CYP2B6 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP2B6 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr19_40991224">chr19:40991224</td>
                  <td id="rs34223104">rs34223104</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *22 *34 *35 *36 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991367">chr19:40991367</td>
                  <td id="rs34883432">rs34883432</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991369">chr19:40991369</td>
                  <td id="rs8192709">rs8192709</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *2 *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991381">chr19:40991381</td>
                  <td id="rs33973337">rs33973337</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991388">chr19:40991388</td>
                  <td id="rs33980385">rs33980385</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991390">chr19:40991390</td>
                  <td id="rs33926104">rs33926104</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991391">chr19:40991391</td>
                  <td id="rs34284776">rs34284776</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_40991441">chr19:40991441</td>
                  <td id="rs35303484">rs35303484</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004015">chr19:41004015</td>
                  <td id="rs281864907">rs281864907</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004125">chr19:41004125</td>
                  <td id="rs36060847">rs36060847</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004158">chr19:41004158</td>
                  <td id="rs186335453">rs186335453</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004303">chr19:41004303</td>
                  <td id="rs139801276">rs139801276</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004377">chr19:41004377</td>
                  <td id="rs12721655">rs12721655</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *8 *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004381">chr19:41004381</td>
                  <td id="rs35773040">rs35773040</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *14 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41004406">chr19:41004406</td>
                  <td id="rs145884402">rs145884402</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41006919">chr19:41006919</td>
                  <td id="rs3826711">rs3826711</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *26 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41006923">chr19:41006923</td>
                  <td id="rs36056539">rs36056539</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *20 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41006936">chr19:41006936</td>
                  <td id="rs3745274">rs3745274</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *6 *7 *9 *13 *19 *20 *26 *34 *36 *37 *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41006968">chr19:41006968</td>
                  <td id="rs373489637">rs373489637</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41007013">chr19:41007013</td>
                  <td id="rs36079186">rs36079186</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *27 *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41009350">chr19:41009350</td>
                  <td id="rs45482602">rs45482602</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *3 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41009358">chr19:41009358</td>
                  <td id="rs2279343">rs2279343</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *4 *6 *7 *13 *18 *19 *20 *26 *34 *36 *37 *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41010006">chr19:41010006</td>
                  <td id="rs139029625">rs139029625</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41010088">chr19:41010088</td>
                  <td id="rs34698757">rs34698757</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41010108">chr19:41010108</td>
                  <td id="rs193922917">rs193922917</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012316">chr19:41012316</td>
                  <td id="rs28399499">rs28399499</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012339">chr19:41012339</td>
                  <td id="rs34826503">rs34826503</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012465">chr19:41012465</td>
                  <td id="rs34097093">rs34097093</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012693">chr19:41012693</td>
                  <td id="rs35979566">rs35979566</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *15 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012740">chr19:41012740</td>
                  <td id="rs193922918">rs193922918</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *32 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41012803">chr19:41012803</td>
                  <td id="rs35010098">rs35010098</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *21 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41016726">chr19:41016726</td>
                  <td id="rs3211369">rs3211369</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41016778">chr19:41016778</td>
                  <td id="rs564083989">rs564083989</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *24 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41016805">chr19:41016805</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *25 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_41016810">chr19:41016810</td>
                  <td id="rs3211371">rs3211371</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *5 *7 *33 *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CYP2C19">
        <h3 id="CYP2C19">CYP2C19 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *38/*38
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP2C19 *38 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr10_94761900">chr10:94761900</td>
                  <td id="rs12248560">rs12248560</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *4 *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762706">chr10:94762706</td>
                  <td id="rs28399504">rs28399504</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *4 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762712">chr10:94762712</td>
                  <td id="rs367543002">rs367543002</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762715">chr10:94762715</td>
                  <td id="rs367543003">rs367543003</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *1 *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762755">chr10:94762755</td>
                  <td id="rs55752064">rs55752064</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *1 *14 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762760">chr10:94762760</td>
                  <td id="rs17882687">rs17882687</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *15 *28 *35 *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762788">chr10:94762788</td>
                  <td id="rs1564656981">rs1564656981</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *29 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94762856">chr10:94762856</td>
                  <td id="rs1564657013">rs1564657013</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775106">chr10:94775106</td>
                  <td id="rs145328984">rs145328984</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *30 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775121">chr10:94775121</td>
                  <td id="rs1564660997">rs1564660997</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775160">chr10:94775160</td>
                  <td id="rs118203756">rs118203756</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775185">chr10:94775185</td>
                  <td id="rs1288601658">rs1288601658</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *32 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775367">chr10:94775367</td>
                  <td id="rs12769205">rs12769205</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *2 *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775416">chr10:94775416</td>
                  <td id="rs41291556">rs41291556</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *1 *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775423">chr10:94775423</td>
                  <td id="rs17885179">rs17885179</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775453">chr10:94775453</td>
                  <td id="rs72552267">rs72552267</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775489">chr10:94775489</td>
                  <td id="rs17884712">rs17884712</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94775507">chr10:94775507</td>
                  <td id="rs58973490">rs58973490</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *2 *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94780574">chr10:94780574</td>
                  <td id="rs140278421">rs140278421</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *22 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94780579">chr10:94780579</td>
                  <td id="rs370803989">rs370803989</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94780653">chr10:94780653</td>
                  <td id="rs4986893">rs4986893</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *3 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94781858">chr10:94781858</td>
                  <td id="rs6413438">rs6413438</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94781859">chr10:94781859</td>
                  <td id="rs4244285">rs4244285</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *2 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94781944">chr10:94781944</td>
                  <td id="rs375781227">rs375781227</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *26 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94781999">chr10:94781999</td>
                  <td id="rs72558186">rs72558186</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *1 *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94842861">chr10:94842861</td>
                  <td id="rs138142612">rs138142612</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94842866">chr10:94842866</td>
                  <td id="rs3758581">rs3758581</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *2 *3 *4 *5 *6 *7 *8 *9 *10 *11 *12 *13 *14 *15 *17 *18 *19 *22 *23 *24 *25 *26 *28 *29 *31 *32 *33 *35 *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94842879">chr10:94842879</td>
                  <td id="rs118203757">rs118203757</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *24 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94842995">chr10:94842995</td>
                  <td id="rs113934938">rs113934938</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *1 *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94849995">chr10:94849995</td>
                  <td id="rs17879685">rs17879685</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94852738">chr10:94852738</td>
                  <td id="rs56337013">rs56337013</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *5 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94852765">chr10:94852765</td>
                  <td id="rs192154563">rs192154563</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *16 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94852785">chr10:94852785</td>
                  <td id="rs118203759">rs118203759</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *1 *25 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94852914">chr10:94852914</td>
                  <td id="rs55640102">rs55640102</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *1 *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CYP2C9">
        <h3 id="CYP2C9">CYP2C9 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP2C9 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr10_94938683">chr10:94938683</td>
                  <td id="rs114071557">rs114071557</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *36 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938719">chr10:94938719</td>
                  <td id=""></td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *80 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938737">chr10:94938737</td>
                  <td id="rs67807361">rs67807361</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938771">chr10:94938771</td>
                  <td id="rs142240658">rs142240658</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *21 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938788">chr10:94938788</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *83 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938800">chr10:94938800</td>
                  <td id="rs1364419386">rs1364419386</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *76 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938803">chr10:94938803</td>
                  <td id="rs2031308986">rs2031308986</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *22 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94938828">chr10:94938828</td>
                  <td id="rs564813580">rs564813580</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941897">chr10:94941897</td>
                  <td id="rs371055887">rs371055887</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *20 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941915">chr10:94941915</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941958">chr10:94941958</td>
                  <td id="rs72558187">rs72558187</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941975">chr10:94941975</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *77 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941976">chr10:94941976</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94941982">chr10:94941982</td>
                  <td id="rs762239445">rs762239445</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942018">chr10:94942018</td>
                  <td id=""></td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *40 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942205">chr10:94942205</td>
                  <td id="rs1304490498">rs1304490498</td>
                  
                  
                    <td class="">CAATGGAAAGA/CAATGGAAAGA</td>
                  
                  <td>
                    CAATGGAAAGA
                  </td>
                  <td>
                    *25 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942216">chr10:94942216</td>
                  <td id="rs774607211">rs774607211</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *41 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942230">chr10:94942230</td>
                  <td id="rs767576260">rs767576260</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *43 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942231">chr10:94942231</td>
                  <td id="rs12414460">rs12414460</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *42 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942233">chr10:94942233</td>
                  <td id="rs375805362">rs375805362</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *62 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942234">chr10:94942234</td>
                  <td id="rs72558189">rs72558189</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *14 *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942243">chr10:94942243</td>
                  <td id="rs1375956433">rs1375956433</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *78 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942249">chr10:94942249</td>
                  <td id="rs200965026">rs200965026</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *26 *44 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942254">chr10:94942254</td>
                  <td id="rs199523631">rs199523631</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *45 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942255">chr10:94942255</td>
                  <td id="rs200183364">rs200183364</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942290">chr10:94942290</td>
                  <td id="rs1799853">rs1799853</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *2 *35 *61 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942291">chr10:94942291</td>
                  <td id="rs141489852">rs141489852</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *63 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942305">chr10:94942305</td>
                  <td id="rs754487195">rs754487195</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *46 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942306">chr10:94942306</td>
                  <td id="rs1289704600">rs1289704600</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *72 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942308">chr10:94942308</td>
                  <td id="rs17847037">rs17847037</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *73 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94942309">chr10:94942309</td>
                  <td id="rs7900194">rs7900194</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *8 *27 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947782">chr10:94947782</td>
                  <td id="rs72558190">rs72558190</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *15 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947785">chr10:94947785</td>
                  <td id="rs774550549">rs774550549</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *47 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947869">chr10:94947869</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *69 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947907">chr10:94947907</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *57 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947917">chr10:94947917</td>
                  <td id="rs1326630788">rs1326630788</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *48 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947938">chr10:94947938</td>
                  <td id="rs2031531005">rs2031531005</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94947939">chr10:94947939</td>
                  <td id="rs370100007">rs370100007</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *74 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949129">chr10:94949129</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *49 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949144">chr10:94949144</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *50 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949145">chr10:94949145</td>
                  <td id="rs772782449">rs772782449</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *82 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949161">chr10:94949161</td>
                  <td id=""></td>
                  
                  
                    <td class="">AT/AT</td>
                  
                  <td>
                    AT
                  </td>
                  <td>
                    *85 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949217">chr10:94949217</td>
                  <td id="rs2256871">rs2256871</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949280">chr10:94949280</td>
                  <td id="rs9332130">rs9332130</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *10 *71 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94949281">chr10:94949281</td>
                  <td id="rs9332131">rs9332131</td>
                  
                  
                    <td class="">GA/GA</td>
                  
                  <td>
                    GA
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972119">chr10:94972119</td>
                  <td id="rs182132442">rs182132442</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *29 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972123">chr10:94972123</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *64 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972134">chr10:94972134</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *51 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972179">chr10:94972179</td>
                  <td id="rs72558192">rs72558192</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *16 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972180">chr10:94972180</td>
                  <td id="rs988617574">rs988617574</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *52 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972183">chr10:94972183</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *81 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94972233">chr10:94972233</td>
                  <td id="rs1237225311">rs1237225311</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *53 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981199">chr10:94981199</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *65 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981201">chr10:94981201</td>
                  <td id="rs57505750">rs57505750</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981224">chr10:94981224</td>
                  <td id="rs28371685">rs28371685</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981225">chr10:94981225</td>
                  <td id="rs367826293">rs367826293</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981230">chr10:94981230</td>
                  <td id="rs1274535931">rs1274535931</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *58 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981250">chr10:94981250</td>
                  <td id="rs750820937">rs750820937</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *54 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981258">chr10:94981258</td>
                  <td id="rs1297714792">rs1297714792</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *79 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981281">chr10:94981281</td>
                  <td id="rs749060448">rs749060448</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *24 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981296">chr10:94981296</td>
                  <td id="rs1057910">rs1057910</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *3 *18 *68 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981297">chr10:94981297</td>
                  <td id="rs56165452">rs56165452</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *4 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981301">chr10:94981301</td>
                  <td id="rs28371686">rs28371686</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *5 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981302">chr10:94981302</td>
                  <td id="rs1250577724">rs1250577724</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *55 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981305">chr10:94981305</td>
                  <td id="rs578144976">rs578144976</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *66 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981365">chr10:94981365</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94981371">chr10:94981371</td>
                  <td id="rs542577750">rs542577750</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *68 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94986042">chr10:94986042</td>
                  <td id="rs764211126">rs764211126</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *56 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94986073">chr10:94986073</td>
                  <td id="rs72558193">rs72558193</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94986136">chr10:94986136</td>
                  <td id="rs1254213342">rs1254213342</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *75 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94986174">chr10:94986174</td>
                  <td id="rs1441296358">rs1441296358</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *84 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988852">chr10:94988852</td>
                  <td id="rs776908257">rs776908257</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *67 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988855">chr10:94988855</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *59 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988880">chr10:94988880</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *70 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988917">chr10:94988917</td>
                  <td id="rs769942899">rs769942899</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988925">chr10:94988925</td>
                  <td id="rs202201137">rs202201137</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *61 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988955">chr10:94988955</td>
                  <td id="rs767284820">rs767284820</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *60 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94988984">chr10:94988984</td>
                  <td id="rs781583846">rs781583846</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *30 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94989020">chr10:94989020</td>
                  <td id="rs9332239">rs9332239</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *12 *71 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr10_94989023">chr10:94989023</td>
                  <td id="rs868182778">rs868182778</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *32 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          
            <h4>Other Positions of Interest</h4>
            
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="94645745">chr10:94645745</td>
                  <td id="rs12777823">rs12777823</td>
                  
                  
                    <td class="">G/G</td>
                  
                </tr>
              
              </tbody>
            </table>
          

        

      </section>
    
      <section class="gene CYP2D6">
        <h3 id="CYP2D6">CYP2D6 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Reported:</th>
              <td class="top-aligned">
                
                  *1/*3
                
              </td>
            </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning pcat-outside-call">This comes from an outside data source which does not supply position-level detail.  For specific disclaimers and limitations, see the original genotyping source.</div>
        

        
          

          

        

      </section>
    
      <section class="gene CYP3A4">
        <h3 id="CYP3A4">CYP3A4 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP3A4 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        
          <div class="alert alert-warning CYP3A4">The CYP3A4 alleles are determined based on PharmVar CYP3A4 allele definitions. See PharmCAT disclaimer for further information.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr7_99758183">chr7:99758183</td>
                  <td id="rs67666821">rs67666821</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *20 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99760836">chr7:99760836</td>
                  <td id="rs4986913">rs4986913</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99760901">chr7:99760901</td>
                  <td id="rs4986910">rs4986910</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *3 *37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99760956">chr7:99760956</td>
                  <td id="rs774109750">rs774109750</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99762047">chr7:99762047</td>
                  <td id="rs4986909">rs4986909</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99762177">chr7:99762177</td>
                  <td id="rs12721629">rs12721629</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99762186">chr7:99762186</td>
                  <td id="rs756833413">rs756833413</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99762206">chr7:99762206</td>
                  <td id="rs67784355">rs67784355</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99763843">chr7:99763843</td>
                  <td id="rs2242480">rs2242480</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *8 *9 *12 *15 *16 *18 *19 *23 *24 *28 *36 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99763877">chr7:99763877</td>
                  <td id="rs368296206">rs368296206</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *32 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99763909">chr7:99763909</td>
                  <td id="rs1303250043">rs1303250043</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99763925">chr7:99763925</td>
                  <td id=""></td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *21 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99764003">chr7:99764003</td>
                  <td id="rs28371759">rs28371759</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99766411">chr7:99766411</td>
                  <td id="rs4646438">rs4646438</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99766440">chr7:99766440</td>
                  <td id="rs138105638">rs138105638</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *26 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768360">chr7:99768360</td>
                  <td id="rs55785340">rs55785340</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *2 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768371">chr7:99768371</td>
                  <td id="rs55901263">rs55901263</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *5 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768424">chr7:99768424</td>
                  <td id="rs113667357">rs113667357</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *24 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768458">chr7:99768458</td>
                  <td id="rs4987161">rs4987161</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768470">chr7:99768470</td>
                  <td id="rs12721627">rs12721627</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *16 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99768693">chr7:99768693</td>
                  <td id="rs35599367">rs35599367</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *22 *37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99769769">chr7:99769769</td>
                  <td id="rs4986908">rs4986908</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99769781">chr7:99769781</td>
                  <td id="rs72552798">rs72552798</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99769804">chr7:99769804</td>
                  <td id="rs4986907">rs4986907</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *15 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99769805">chr7:99769805</td>
                  <td id="rs57409622">rs57409622</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99770165">chr7:99770165</td>
                  <td id="rs72552799">rs72552799</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99770166">chr7:99770166</td>
                  <td id="rs778013004">rs778013004</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *30 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99770202">chr7:99770202</td>
                  <td id="rs55951658">rs55951658</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *4 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99770217">chr7:99770217</td>
                  <td id="rs1449865051">rs1449865051</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *29 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99778079">chr7:99778079</td>
                  <td id="rs56324128">rs56324128</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99784018">chr7:99784018</td>
                  <td id="rs570051168">rs570051168</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99784038">chr7:99784038</td>
                  <td id="rs12721634">rs12721634</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *14 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99784075">chr7:99784075</td>
                  <td id="rs188389063">rs188389063</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CYP3A5">
        <h3 id="CYP3A5">CYP3A5 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP3A5 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr7_99652770">chr7:99652770</td>
                  <td id="rs41303343">rs41303343</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99660516">chr7:99660516</td>
                  <td id="rs28383479">rs28383479</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99665212">chr7:99665212</td>
                  <td id="rs10264272">rs10264272</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99672916">chr7:99672916</td>
                  <td id="rs776746">rs776746</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *3 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr7_99676198">chr7:99676198</td>
                  <td id="rs55817950">rs55817950</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene CYP4F2">
        <h3 id="CYP4F2">CYP4F2 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The CYP4F2 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr19_15879621">chr19:15879621</td>
                  <td id="rs2108622">rs2108622</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *3 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_15897578">chr19:15897578</td>
                  <td id="rs3093105">rs3093105</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *2 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene DPYD">
        <h3 id="DPYD">DPYD allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  Reference/Reference
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The DPYD Reference allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        
          <div class="alert alert-warning DPYD-lowest-activity-score-note">The two lowest activity values (variant activity scores, see CPIC guideline PMID: 29152729) are used to determine the gene activity score and phenotype type to retrieve prescribing recommendations. </div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr1_97078987">chr1:97078987</td>
                  <td id="rs114096998">rs114096998</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.3067C&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97078993">chr1:97078993</td>
                  <td id="rs148799944">rs148799944</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.3061G&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079005">chr1:97079005</td>
                  <td id="rs140114515">rs140114515</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.3049G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079071">chr1:97079071</td>
                  <td id="rs1801268">rs1801268</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2983G&gt;T (*10) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079076">chr1:97079076</td>
                  <td id="rs139459586">rs139459586</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.2978T&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079077">chr1:97079077</td>
                  <td id="rs202144771">rs202144771</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2977C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079121">chr1:97079121</td>
                  <td id="rs72547601">rs72547601</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2933A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079133">chr1:97079133</td>
                  <td id="rs72547602">rs72547602</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2921A&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97079139">chr1:97079139</td>
                  <td id="rs145529148">rs145529148</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2915A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97082365">chr1:97082365</td>
                  <td id="rs141044036">rs141044036</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2872A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97082391">chr1:97082391</td>
                  <td id="rs67376798">rs67376798</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2846A&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97098598">chr1:97098598</td>
                  <td id="rs1801267">rs1801267</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2657G&gt;A (*9B) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97098599">chr1:97098599</td>
                  <td id="rs147545709">rs147545709</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2656C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97098616">chr1:97098616</td>
                  <td id="rs55674432">rs55674432</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2639G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97098632">chr1:97098632</td>
                  <td id="rs201035051">rs201035051</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2623A&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97193109">chr1:97193109</td>
                  <td id="rs60139309">rs60139309</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.2582A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97193209">chr1:97193209</td>
                  <td id="rs200687447">rs200687447</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2482G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97234958">chr1:97234958</td>
                  <td id="rs199634007">rs199634007</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2336C&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97234991">chr1:97234991</td>
                  <td id="rs56005131">rs56005131</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2303C&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97305279">chr1:97305279</td>
                  <td id="rs112766203">rs112766203</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2279C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97305363">chr1:97305363</td>
                  <td id="rs60511679">rs60511679</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.2195T&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97305364">chr1:97305364</td>
                  <td id="rs1801160">rs1801160</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2194G&gt;A (*6) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97305372">chr1:97305372</td>
                  <td id="rs146529561">rs146529561</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.2186C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97306195">chr1:97306195</td>
                  <td id="rs145548112">rs145548112</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2161G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97373598">chr1:97373598</td>
                  <td id="rs137999090">rs137999090</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.2021G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97373629">chr1:97373629</td>
                  <td id="rs138545885">rs138545885</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1990G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97382461">chr1:97382461</td>
                  <td id="rs55971861">rs55971861</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.1906A&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450058">chr1:97450058</td>
                  <td id="rs3918290">rs3918290</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1905+1G&gt;A (*2A) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450059">chr1:97450059</td>
                  <td id="rs3918289">rs3918289</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1905C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450065">chr1:97450065</td>
                  <td id="rs72549303">rs72549303</td>
                  
                  
                    <td class="">TG/TG</td>
                  
                  <td>
                    TG
                  </td>
                  <td>
                    c.1898delC (*3) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450068">chr1:97450068</td>
                  <td id="rs17376848">rs17376848</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1896T&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450168">chr1:97450168</td>
                  <td id="rs147601618">rs147601618</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1796T&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450187">chr1:97450187</td>
                  <td id="rs145773863">rs145773863</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1777G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450189">chr1:97450189</td>
                  <td id="rs138616379">rs138616379</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1775G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97450190">chr1:97450190</td>
                  <td id="rs59086055">rs59086055</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1774C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515784">chr1:97515784</td>
                  <td id="rs201615754">rs201615754</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1682G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515787">chr1:97515787</td>
                  <td id="rs55886062">rs55886062</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1679T&gt;G (*13) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515839">chr1:97515839</td>
                  <td id="rs1801159">rs1801159</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.1627A&gt;G (*5) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515851">chr1:97515851</td>
                  <td id="rs142619737">rs142619737</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1615G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515865">chr1:97515865</td>
                  <td id="rs1801158">rs1801158</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1601G&gt;A (*4) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515889">chr1:97515889</td>
                  <td id="rs190951787">rs190951787</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1577C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97515923">chr1:97515923</td>
                  <td id="rs148994843">rs148994843</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1543G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549565">chr1:97549565</td>
                  <td id="rs138391898">rs138391898</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1519G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549600">chr1:97549600</td>
                  <td id="rs111858276">rs111858276</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.1484A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549609">chr1:97549609</td>
                  <td id="rs72549304">rs72549304</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1475C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549681">chr1:97549681</td>
                  <td id="rs199549923">rs199549923</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1403C&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549713">chr1:97549713</td>
                  <td id="rs57918000">rs57918000</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1371C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549726">chr1:97549726</td>
                  <td id="rs144395748">rs144395748</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1358C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97549735">chr1:97549735</td>
                  <td id="rs72975710">rs72975710</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1349C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573785">chr1:97573785</td>
                  <td id="rs186169810">rs186169810</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1314T&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573805">chr1:97573805</td>
                  <td id="rs142512579">rs142512579</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1294G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573821">chr1:97573821</td>
                  <td id="rs764666241">rs764666241</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1278G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573839">chr1:97573839</td>
                  <td id="rs200064537">rs200064537</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1260T&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573863">chr1:97573863</td>
                  <td id="rs56038477">rs56038477</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1129-5923C&gt;G, c.1236G&gt;A (HapB3) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573881">chr1:97573881</td>
                  <td id="rs61622928">rs61622928</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1218G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573918">chr1:97573918</td>
                  <td id="rs143815742">rs143815742</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1181G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573919">chr1:97573919</td>
                  <td id="rs140602333">rs140602333</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1180C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97573943">chr1:97573943</td>
                  <td id="rs78060119">rs78060119</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1156G&gt;T (*12) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97579893">chr1:97579893</td>
                  <td id="rs75017182">rs75017182</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1129-5923C&gt;G, c.1236G&gt;A (HapB3) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97593238">chr1:97593238</td>
                  <td id="rs72549305">rs72549305</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.1108A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97593289">chr1:97593289</td>
                  <td id="rs143154602">rs143154602</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1057C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97593322">chr1:97593322</td>
                  <td id="rs183385770">rs183385770</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1024G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97593343">chr1:97593343</td>
                  <td id="rs72549306">rs72549306</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1003G&gt;T (*11) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97593379">chr1:97593379</td>
                  <td id="rs201018345">rs201018345</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.967G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97595083">chr1:97595083</td>
                  <td id="rs145112791">rs145112791</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.934C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97595088">chr1:97595088</td>
                  <td id="rs150437414">rs150437414</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.929T&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97595149">chr1:97595149</td>
                  <td id="rs146356975">rs146356975</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.868A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97679170">chr1:97679170</td>
                  <td id="rs45589337">rs45589337</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.775A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97691776">chr1:97691776</td>
                  <td id="rs1801266">rs1801266</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.703C&gt;T (*8) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699399">chr1:97699399</td>
                  <td id="rs72549307">rs72549307</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.632A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699430">chr1:97699430</td>
                  <td id="rs72549308">rs72549308</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.601A&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699474">chr1:97699474</td>
                  <td id="rs115232898">rs115232898</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.557A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699506">chr1:97699506</td>
                  <td id="rs6670886">rs6670886</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.525G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699533">chr1:97699533</td>
                  <td id="rs139834141">rs139834141</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.498G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97699535">chr1:97699535</td>
                  <td id="rs2297595">rs2297595</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.496A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97721542">chr1:97721542</td>
                  <td id="rs200562975">rs200562975</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.451A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97721650">chr1:97721650</td>
                  <td id="rs141462178">rs141462178</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.343A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97740400">chr1:97740400</td>
                  <td id="rs150385342">rs150385342</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.313G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97740410">chr1:97740410</td>
                  <td id="rs72549309">rs72549309</td>
                  
                  
                    <td class="">GATGA/GATGA</td>
                  
                  <td>
                    GATGA
                  </td>
                  <td>
                    c.295_298delTCAT (*7) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97883329">chr1:97883329</td>
                  <td id="rs1801265">rs1801265</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.85T&gt;C (*9A) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97883352">chr1:97883352</td>
                  <td id="rs80081766">rs80081766</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.62G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97883353">chr1:97883353</td>
                  <td id="rs72549310">rs72549310</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.61C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr1_97883368">chr1:97883368</td>
                  <td id="rs150036960">rs150036960</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.46C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene G6PD">
        <h3 id="G6PD">G6PD allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Reported:</th>
              <td class="top-aligned">
                
                  B (wildtype)/B (wildtype)
                
              </td>
            </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning pcat-outside-call">This comes from an outside data source which does not supply position-level detail.  For specific disclaimers and limitations, see the original genotyping source.</div>
        
          <div class="alert alert-warning prefer-sample-data">PharmCAT would have called B (reference)/B (reference) based on the VCF but it has been ignored in favor of the outside call. If you want to use the PharmCAT call for this gene then remove the gene from the outside call data.</div>
        

        
          

          

        

      </section>
    
      <section class="gene HLA-B">
        <h3 id="HLA-B">HLA-B allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Reported:</th>
              <td class="top-aligned">
                
                  *15:02/*57:01
                
              </td>
            </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning pcat-outside-call">This comes from an outside data source which does not supply position-level detail.  For specific disclaimers and limitations, see the original genotyping source.</div>
        

        
          

          

        

      </section>
    
      <section class="gene IFNL3/4">
        <h3 id="IFNL3/4">IFNL3/4 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  rs12979860 reference (C)/rs12979860 reference (C)
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr19_39248147">chr19:39248147</td>
                  <td id="rs12979860">rs12979860</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    rs12979860 variant (T) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene MT-RNR1">
        <h3 id="MT-RNR1">MT-RNR1 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Reported:</th>
              <td class="top-aligned">
                
                  1555A&gt;G
                
              </td>
            </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning pcat-outside-call">This comes from an outside data source which does not supply position-level detail.  For specific disclaimers and limitations, see the original genotyping source.</div>
        

        
          

          

        

      </section>
    
      <section class="gene NUDT15">
        <h3 id="NUDT15">NUDT15 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The NUDT15 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr13_48037748">chr13:48037748</td>
                  <td id="rs769369441">rs769369441</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037749">chr13:48037749</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037782">chr13:48037782</td>
                  <td id="rs746071566">rs746071566</td>
                  
                  
                    <td class="">AGGAGTC/AGGAGTC</td>
                  
                  <td>
                    AGGAGTC
                  </td>
                  <td>
                    *2 *6 *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037798">chr13:48037798</td>
                  <td id="rs186364861">rs186364861</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *5 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037825">chr13:48037825</td>
                  <td id="rs777311140">rs777311140</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *14 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037834">chr13:48037834</td>
                  <td id="rs1202487323">rs1202487323</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *16 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037847">chr13:48037847</td>
                  <td id="rs766023281">rs766023281</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037849">chr13:48037849</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037885">chr13:48037885</td>
                  <td id="rs1950545307">rs1950545307</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48037902">chr13:48037902</td>
                  <td id="rs149436418">rs149436418</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48040977">chr13:48040977</td>
                  <td id="rs1457579126">rs1457579126</td>
                  
                  
                    <td class="">GA/GA</td>
                  
                  <td>
                    GA
                  </td>
                  <td>
                    *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48041103">chr13:48041103</td>
                  <td id="rs761191455">rs761191455</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48041113">chr13:48041113</td>
                  <td id="rs1368252918">rs1368252918</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48045690">chr13:48045690</td>
                  <td id="rs768324690">rs768324690</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *20 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48045719">chr13:48045719</td>
                  <td id="rs116855232">rs116855232</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *2 *3 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48045720">chr13:48045720</td>
                  <td id="rs147390019">rs147390019</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *4 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr13_48045771">chr13:48045771</td>
                  <td id="rs139551410">rs139551410</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *15 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene RYR1">
        <h3 id="RYR1">RYR1 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  Reference/Reference
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The RYR1 Reference allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr19_38440802">chr19:38440802</td>
                  <td id="rs193922747">rs193922747</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.103T&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38440829">chr19:38440829</td>
                  <td id="rs193922748">rs193922748</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.130C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38444211">chr19:38444211</td>
                  <td id="rs118192161">rs118192161</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.487C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38444212">chr19:38444212</td>
                  <td id="rs193922753">rs193922753</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.488G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38446710">chr19:38446710</td>
                  <td id="rs1801086">rs1801086</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.742G&gt;A c.742G&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38448673">chr19:38448673</td>
                  <td id="rs193922762">rs193922762</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.982C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38448712">chr19:38448712</td>
                  <td id="rs121918592">rs121918592</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1021G&gt;A c.1021G&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38451842">chr19:38451842</td>
                  <td id="rs193922764">rs193922764</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1201C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38451850">chr19:38451850</td>
                  <td id="rs118192116">rs118192116</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1209C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38455359">chr19:38455359</td>
                  <td id="rs118192162">rs118192162</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.1565A&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38455463">chr19:38455463</td>
                  <td id="rs111888148">rs111888148</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1589G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38455471">chr19:38455471</td>
                  <td id="rs193922768">rs193922768</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1597C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38455472">chr19:38455472</td>
                  <td id="rs144336148">rs144336148</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1598G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38455528">chr19:38455528</td>
                  <td id="rs193922770">rs193922770</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1654C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38457545">chr19:38457545</td>
                  <td id="rs118192172">rs118192172</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.1840C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38457546">chr19:38457546</td>
                  <td id="rs193922772">rs193922772</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.1841G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38494564">chr19:38494564</td>
                  <td id="rs118192175">rs118192175</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.6487C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38494565">chr19:38494565</td>
                  <td id="rs118192163">rs118192163</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.6488G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38494579">chr19:38494579</td>
                  <td id="rs118192176">rs118192176</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.6502G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38496283">chr19:38496283</td>
                  <td id="rs118192177">rs118192177</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.6617C&gt;G c.6617C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499223">chr19:38499223</td>
                  <td id="rs112563513">rs112563513</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7007G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499644">chr19:38499644</td>
                  <td id="rs121918596">rs121918596</td>
                  
                  
                    <td class="">TGGA/TGGA</td>
                  
                  <td>
                    TGGA
                  </td>
                  <td>
                    c.7042_7044delGAG 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499655">chr19:38499655</td>
                  <td id="rs193922802">rs193922802</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7048G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499670">chr19:38499670</td>
                  <td id="rs193922803">rs193922803</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.7063C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499731">chr19:38499731</td>
                  <td id="rs193922807">rs193922807</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7124G&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499975">chr19:38499975</td>
                  <td id="rs193922809">rs193922809</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7282G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499993">chr19:38499993</td>
                  <td id="rs121918593">rs121918593</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7300G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38499997">chr19:38499997</td>
                  <td id="rs28933396">rs28933396</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7304G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500636">chr19:38500636</td>
                  <td id="rs118192124">rs118192124</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.7354C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500642">chr19:38500642</td>
                  <td id="rs193922816">rs193922816</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.7360C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500643">chr19:38500643</td>
                  <td id="rs118192122">rs118192122</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7361G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500654">chr19:38500654</td>
                  <td id="rs28933397">rs28933397</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.7372C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500655">chr19:38500655</td>
                  <td id="rs121918594">rs121918594</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7373G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500898">chr19:38500898</td>
                  <td id="rs118192178">rs118192178</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.7522C&gt;G c.7522C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38500899">chr19:38500899</td>
                  <td id="rs193922818">rs193922818</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.7523G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38512321">chr19:38512321</td>
                  <td id="rs193922832">rs193922832</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.9310G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38543832">chr19:38543832</td>
                  <td id="rs193922843">rs193922843</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.11969G&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580004">chr19:38580004</td>
                  <td id="rs118192167">rs118192167</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    c.14387A&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580094">chr19:38580094</td>
                  <td id="rs121918595">rs121918595</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.14477C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580114">chr19:38580114</td>
                  <td id="rs193922876">rs193922876</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.14497C&gt;T 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580370">chr19:38580370</td>
                  <td id="rs193922878">rs193922878</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    c.14512C&gt;G 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580403">chr19:38580403</td>
                  <td id="rs118192168">rs118192168</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.14545G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38580440">chr19:38580440</td>
                  <td id="rs63749869">rs63749869</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    c.14582G&gt;A 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr19_38584989">chr19:38584989</td>
                  <td id="rs118192170">rs118192170</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    c.14693T&gt;C 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene SLCO1B1">
        <h3 id="SLCO1B1">SLCO1B1 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The SLCO1B1 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        
          <div class="alert alert-warning SLCO1B1-drug-text">The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 defines SLCO1B1*5.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr12_21172734">chr12:21172734</td>
                  <td id="rs139257324">rs139257324</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21172776">chr12:21172776</td>
                  <td id="rs373327528">rs373327528</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21172782">chr12:21172782</td>
                  <td id="rs56101265">rs56101265</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *2 *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21174595">chr12:21174595</td>
                  <td id="rs56061388">rs56061388</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *3 *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176804">chr12:21176804</td>
                  <td id="rs2306283">rs2306283</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *14 *15 *20 *24 *25 *27 *28 *29 *30 *31 *32 *33 *37 *39 *42 *43 *44 *46 *47 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176868">chr12:21176868</td>
                  <td id="rs2306282">rs2306282</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *16 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176871">chr12:21176871</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176879">chr12:21176879</td>
                  <td id="rs11045819">rs11045819</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *4 *14 *25 *32 *43 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176883">chr12:21176883</td>
                  <td id="rs72559745">rs72559745</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *3 *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21176898">chr12:21176898</td>
                  <td id="rs77271279">rs77271279</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *41 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21178612">chr12:21178612</td>
                  <td id="rs141467543">rs141467543</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *42 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21178615">chr12:21178615</td>
                  <td id="rs4149056">rs4149056</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *5 *15 *40 *46 *47 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21178957">chr12:21178957</td>
                  <td id="rs79135870">rs79135870</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *30 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21196951">chr12:21196951</td>
                  <td id="rs11045852">rs11045852</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *24 *25 *28 *32 *33 *43 *44 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21196975">chr12:21196975</td>
                  <td id="rs183501729">rs183501729</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21196976">chr12:21196976</td>
                  <td id="rs11045853">rs11045853</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *25 *28 *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21200544">chr12:21200544</td>
                  <td id="rs72559747">rs72559747</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *47 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21200595">chr12:21200595</td>
                  <td id="rs55901008">rs55901008</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21202553">chr12:21202553</td>
                  <td id="rs1228465562">rs1228465562</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *36 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21202555">chr12:21202555</td>
                  <td id="rs59113707">rs59113707</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *27 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21202649">chr12:21202649</td>
                  <td id="rs56387224">rs56387224</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21202664">chr12:21202664</td>
                  <td id="rs142965323">rs142965323</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *26 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21205921">chr12:21205921</td>
                  <td id="rs72559748">rs72559748</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21205999">chr12:21205999</td>
                  <td id="rs59502379">rs59502379</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *9 *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21206031">chr12:21206031</td>
                  <td id="rs74064213">rs74064213</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *43 *44 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21222355">chr12:21222355</td>
                  <td id="rs71581941">rs71581941</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *45 *46 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21239042">chr12:21239042</td>
                  <td id="rs34671512">rs34671512</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *19 *20 *40 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21239077">chr12:21239077</td>
                  <td id="rs56199088">rs56199088</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *10 *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21239113">chr12:21239113</td>
                  <td id="rs55737008">rs55737008</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *11 *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21239145">chr12:21239145</td>
                  <td id="rs200995543">rs200995543</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr12_21239158">chr12:21239158</td>
                  <td id="rs140790673">rs140790673</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *29 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene TPMT">
        <h3 id="TPMT">TPMT allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The TPMT *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr6_18130687">chr6:18130687</td>
                  <td id="rs1142345">rs1142345</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *3A *3C *41 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130694">chr6:18130694</td>
                  <td id="rs150900439">rs150900439</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *20 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130725">chr6:18130725</td>
                  <td id="rs72552736">rs72552736</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *7 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130729">chr6:18130729</td>
                  <td id="rs139392616">rs139392616</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *40 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130758">chr6:18130758</td>
                  <td id="rs398122996">rs398122996</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130762">chr6:18130762</td>
                  <td id="rs56161402">rs56161402</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *8 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130772">chr6:18130772</td>
                  <td id="rs377085266">rs377085266</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *25 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18130781">chr6:18130781</td>
                  <td id="rs1800584">rs1800584</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *4 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18132136">chr6:18132136</td>
                  <td id="rs72556347">rs72556347</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *26 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18132147">chr6:18132147</td>
                  <td id="rs79901429">rs79901429</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *31 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18132163">chr6:18132163</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *36 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133845">chr6:18133845</td>
                  <td id="rs75543815">rs75543815</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133847">chr6:18133847</td>
                  <td id="rs6921269">rs6921269</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *24 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133870">chr6:18133870</td>
                  <td id="rs772832951">rs772832951</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *38 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133884">chr6:18133884</td>
                  <td id="rs74423290">rs74423290</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *23 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133887">chr6:18133887</td>
                  <td id="rs201695576">rs201695576</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *44 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18133890">chr6:18133890</td>
                  <td id="rs9333570">rs9333570</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *15 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18138969">chr6:18138969</td>
                  <td id="rs144041067">rs144041067</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *16 *22 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18138970">chr6:18138970</td>
                  <td id="rs112339338">rs112339338</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *33 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18138997">chr6:18138997</td>
                  <td id="rs1800460">rs1800460</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *3A *3B 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18139027">chr6:18139027</td>
                  <td id="rs72552737">rs72552737</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *10 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18139689">chr6:18139689</td>
                  <td id="rs72552738">rs72552738</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *11 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18139710">chr6:18139710</td>
                  <td id="rs200220210">rs200220210</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *12 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143597">chr6:18143597</td>
                  <td id=""></td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *19 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143606">chr6:18143606</td>
                  <td id="rs151149760">rs151149760</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *9 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143613">chr6:18143613</td>
                  <td id=""></td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *28 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143622">chr6:18143622</td>
                  <td id="rs115106679">rs115106679</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *32 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143643">chr6:18143643</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *27 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143700">chr6:18143700</td>
                  <td id="rs753545734">rs753545734</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *43 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143718">chr6:18143718</td>
                  <td id="rs111901354">rs111901354</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *34 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143724">chr6:18143724</td>
                  <td id="rs1800462">rs1800462</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *2 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18143728">chr6:18143728</td>
                  <td id="rs1256618794">rs1256618794</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *43 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18147838">chr6:18147838</td>
                  <td id="rs281874771">rs281874771</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *39 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18147845">chr6:18147845</td>
                  <td id="rs777686348">rs777686348</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *18 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18147851">chr6:18147851</td>
                  <td id="rs200591577">rs200591577</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *21 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18147856">chr6:18147856</td>
                  <td id=""></td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *35 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18147910">chr6:18147910</td>
                  <td id="rs72552740">rs72552740</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *5 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149004">chr6:18149004</td>
                  <td id=""></td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *17 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149022">chr6:18149022</td>
                  <td id="rs750424422">rs750424422</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *30 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149032">chr6:18149032</td>
                  <td id="rs759836180">rs759836180</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *42 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149045">chr6:18149045</td>
                  <td id="rs72552742">rs72552742</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *13 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149126">chr6:18149126</td>
                  <td id="rs267607275">rs267607275</td>
                  
                  
                    <td class="">A/A</td>
                  
                  <td>
                    A
                  </td>
                  <td>
                    *29 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr6_18149127">chr6:18149127</td>
                  <td id="rs9333569">rs9333569</td>
                  
                  
                    <td class="">T/T</td>
                  
                  <td>
                    T
                  </td>
                  <td>
                    *14 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene UGT1A1">
        <h3 id="UGT1A1">UGT1A1 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  *1/*1
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        
          <div class="alert alert-warning reference-allele">The UGT1A1 *1 allele assignment is characterized by the absence of variants at the positions that are included in the underlying allele definitions.</div>
        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr2_233759924">chr2:233759924</td>
                  <td id="rs887829">rs887829</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *80 *80+*28 *80+*37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr2_233760233">chr2:233760233</td>
                  <td id="rs3064744">rs3064744</td>
                  
                  
                    <td class="">CAT/CAT</td>
                  
                  <td>
                    CAT
                  </td>
                  <td>
                    *28 *36 *37 *80+*28 *80+*37 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr2_233760498">chr2:233760498</td>
                  <td id="rs4148323">rs4148323</td>
                  
                  
                    <td class="">G/G</td>
                  
                  <td>
                    G
                  </td>
                  <td>
                    *6 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
                <tr>
                  <td id="chr2_233760973">chr2:233760973</td>
                  <td id="rs35350960">rs35350960</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    *27 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    
      <section class="gene VKORC1">
        <h3 id="VKORC1">VKORC1 allele match data</h3>

        
          <table>
            <tbody>
            <tr>
              <th style="width: 12em;">Genotype Matched:</th>
              <td class="top-aligned">
                
                  rs9923231 reference (C)/rs9923231 reference (C)
                
              </td>
            </tr>
            
              <tr>
                <th>Phasing Status:</th>
                <td class="top-aligned">
                  <p>
                    Unphased
                  </p>
                  
                    <p>
                      PharmCAT reports the genotype(s) that receive the highest score during the matcher process. In
                      case of unphased data, additional genotypes might be possible and cannot be ruled out.
                    </p>
                  
                </td>
              </tr>
            
            
            </tbody>
          </table>
        

        

        
          
            <h4>Calls at Positions</h4>
            <table>
              <thead>
              <tr>
                <th>Position in VCF</th>
                <th>RSID</th>
                <th>Call in VCF</th>
                <th>Reference</th>
                <th>Related Alleles</th>
                <th>Warnings</th>
              </tr>
              </thead>
              <tbody>
              
                <tr>
                  <td id="chr16_31096368">chr16:31096368</td>
                  <td id="rs9923231">rs9923231</td>
                  
                  
                    <td class="">C/C</td>
                  
                  <td>
                    C
                  </td>
                  <td>
                    rs9923231 variant (T) 
                  </td>
                  <td>
                    <ul class="warningList">
                      
                    </ul>
                  </td>
                </tr>
              
              </tbody>
            </table>
          

          

        

      </section>
    

  </section>

  <section id="disclaimer">
  <h2>Section IV: Disclaimers and Other Information</h2>
  <p><strong>Liability: PhamCAT assumes no responsibility for any injury to person or damage to persons or property arising out of,
    or related to any use of PharmCAT, or for any errors or omissions. The user recognizes that PharmCAT is a research tool
    and that they are using PharmCAT at their own risk.</strong>
  </p>
  <h3>A. Allele and Genotype Determination</h3>
  <ol>
    <li>
      <p>PharmCAT uses gene allele definitions included in the CPIC database, with exceptions as noted
        in <a href="https://pharmcat.org/methods/gene-definition-exceptions/"
            rel="nofollow">Gene Definition Exceptions document</a>. For allele
        definitions and the positions used in PharmCAT, see
        the <a href="https://github.com/PharmGKB/PharmCAT/releases">gene definition tables</a>.</p>
    </li>
    <li>
      <p>PharmCAT results are dependent on the supplied vcf calls for the queried positions (for technical information about
        PharmCAT input formatting and requirements, please go to
        <a href="https://pharmcat.org/" rel="nofollow">pharmcat.org</a>). PharmCAT does not assume any reference calls for positions missing from the
        submitted vcf file; all missing queried positions are not considered in the allele determination process. See
        the <a href="https://github.com/PharmGKB/PharmCAT/releases">gene definition tables</a> for more information about what positions
        are queried in the vcf file. Missing positions might alter the assigned genotype, subsequent phenotype prediction and
        CPIC recommendation. If the supplied vcf file is missing positions, those positions will be noted in Section III:
        Allele Matching Details for each gene of this report. For the most reliable allele determination, reference calls as well as
        variant calls in the vcf file for every queried position must be provided by the user.</p>
    </li>
    <li>
      <p>For cytochrome P450 genes, TPMT, NUDT15, UGT1A1, and SLCO1B1, the *1 allele is defined by the absence of variation
        specified in the gene definition tables. This allele cannot be identified by variants; rather, *1 is assigned by
        default when no variation for the queried positions is reported in the submitted vcf file. The same is true for all
        other genes with multiple variant positions in the definition table (CACNA1S, CFTR, DPYD, RYR1): the reference
        sequence is the default result when variants are not reported in the vcf file. It is always possible un-interrogated
        variation can occur which could potentially affect allele function, but because it is undetected, the assignment
        would be defaulted to a *1 (or reference) allele and normal function.</p>
    </li>
    <li>
      <p>For all genes, variation reported in the vcf file but NOT included in the gene definition table will not be
        considered during allele assignment. There is a possibility that any such variation results in a reduced or no
        activity allele which could lead to inaccurate phenotype and CPIC recommendation, similar to the situation in point
        3, above.</p>
    </li>
    <li>
      <p>Nucleotide base calls are displayed on the positive chromosomal strand regardless of the gene strand; further
        information is provided under Gene-specific warnings in Section III: Allele Matching Details.</p>
    </li>
    <li>
      <p>PharmCAT matches variants to genotypes assuming unphased data (unless phased data is provided in the vcf file and
        noted as such, see
        <a href="https://pharmcat.org/" rel="nofollow">pharmcat.org</a> for details). The assumption is that defined alleles exist in trans
        configuration, i.e. on opposite chromosomes, with exceptions noted in Section III: Allele Matching Details under
        "Gene-specific warnings." However, in cases where an allele is defined by a combination of two or more variants,
        where each variant alone also defines an allele, the match is based on the longer allele. For example, TPMT*3B is
        defined by one SNP, *3C is defined by another SNP, and *3A is defined by the combination of those two SNPs. In the
        case of unphased data that is heterozygous for both SNPs, the *1/*3A genotype is returned though the possibility of
        *3B/*3C cannot be ruled out.</p>
      <p>Below cases are summarized for which two calls with different scores are possible when provided unphased data and
        heterozygous calls for the variants that define the two alleles. The genotype with the higher score (longer allele)
        will be used to determine allele functionality, phenotype, and recommendation but the genotype with the lower score
        cannot be ruled out.</p>
    </li>
  </ol>
  <p>Table 1: Cases for which there is an overlap in the allele definitions.</p>
  <table>
    <thead>
    <tr>
      <th>Gene</th>
      <th>Genotype (Higher Score)</th>
      <th>Metabolizer phenotype</th>
      <th>Genotype (Lower Score)</th>
      <th>Metabolizer phenotype</th>
    </tr>
    </thead>
    <tbody>
    <tr>
      <td>UGT1A1</td>
      <td>*1/*80+*28</td>
      <td>Intermediate</td>
      <td>*28/*80</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>UGT1A1</td>
      <td>*1/*80+*37</td>
      <td>Intermediate</td>
      <td>*37/*80</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>TPMT</td>
      <td>*1/*3A</td>
      <td>Intermediate</td>
      <td>*3B/*3C</td>
      <td>Poor</td>
    </tr>
    <tr>
      <td>NUDT15</td>
      <td>*1/*2</td>
      <td>Intermediate</td>
      <td>*3/*6</td>
      <td>Possible Intermediate</td>
    </tr>
    <tr>
      <td>CYP2C9</td>
      <td>*1/*71</td>
      <td>N/A</td>
      <td>*10/*22</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*36</td>
      <td>Intermediate</td>
      <td>*6/*22</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*34</td>
      <td>Intermediate</td>
      <td>*33/*36</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*6</td>
      <td>Intermediate</td>
      <td>*4/*9</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*7</td>
      <td>Intermediate</td>
      <td>*5/*6</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*13</td>
      <td>Intermediate</td>
      <td>*6/*8</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*46</td>
      <td>Decreased function</td>
      <td>*15/*45</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*20</td>
      <td>Normal Function</td>
      <td>*19/*37</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*12</td>
      <td>Indeterminate</td>
      <td>*2/*10</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*13</td>
      <td>Indeterminate</td>
      <td>*3/*11</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*14</td>
      <td>Normal Function</td>
      <td>*4/*37</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*15</td>
      <td>Decreased function</td>
      <td>*5/*37</td>
      <td>Decreased function</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*25</td>
      <td>Indeterminate</td>
      <td>*4/*28</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*31</td>
      <td>Decreased function</td>
      <td>*9/*37</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*32</td>
      <td>Indeterminate</td>
      <td>*4/*24</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*40</td>
      <td>Indeterminate</td>
      <td>*5/*19</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>SLCO1B1</td>
      <td>*1/*43</td>
      <td>Indeterminate</td>
      <td>*4/*44</td>
      <td>Indeterminate</td>
    </tr>
    </tbody>
  </table>
  <p>Table 2: Cases for which there is an overlap in the allele definitions because the definition of the non-*1 allele in
    the genotype with the higher score allows for reference or variant at the position that defines the first allele listed
    in the genotype with the lower score. Both genotypes cannot be ruled out with unphased data if the position that
    overlaps between the respectives alleles is heterozygous (0/1) in addition to heterozyous calls for the other variants
    that define the non-*1 allele in the genotype with the higher score.</p>
  <table>
    <thead>
    <tr>
      <th>Gene</th>
      <th>Genotype (Higher Score)</th>
      <th>Metabolizer phenotype</th>
      <th>Genotype (Lower Score)</th>
      <th>Metabolizer phenotype</th>
    </tr>
    </thead>
    <tbody>
    <tr>
      <td>CYP2C19</td>
      <td>*1/*4</td>
      <td>Intermediate</td>
      <td>*17/*4</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP2C19</td>
      <td>*1/*2</td>
      <td>Intermediate</td>
      <td>*11/*2</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP2C19</td>
      <td>*1/*35</td>
      <td>Intermediate</td>
      <td>*15/*35</td>
      <td>Intermediate</td>
    </tr>
    <tr>
      <td>CYP3A5</td>
      <td>*1/*3</td>
      <td>Intermediate</td>
      <td>*2/*3</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP3A5</td>
      <td>*1/*3</td>
      <td>Intermediate</td>
      <td>*4/*3</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP3A5</td>
      <td>*1/*3</td>
      <td>Intermediate</td>
      <td>*5/*3</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP3A5</td>
      <td>*1/*3</td>
      <td>Intermediate</td>
      <td>*9/*3</td>
      <td>Indeterminate</td>
    </tr>
    <tr>
      <td>CYP2B6</td>
      <td>*1/*18</td>
      <td>Intermediate</td>
      <td>*4/*18</td>
      <td>Indeterminate</td>
    </tr>
    </tbody>
  </table>
  <h3>B. CPIC Allele Function, Phenotype and Recommendation</h3>
  <ol>
    <li>All content is sourced from the <a href="https://github.com/cpicpgx/cpic-data">CPIC database</a>.</li>
  </ol>
  <h3>C. PharmCAT Exceptions to the CPIC Guideline Gene List</h3>
  <ol>
    <li>PharmCAT does not determine CYP2D6, G6PD, MT-RNR1, or HLA genotypes from the vcf file, but genotypes for CYP2D6,
      G6PD, and MT-RNR1 can be provided to PharmCAT from an outside source and the corresponding phenotype and prescribing
      recommendations will be included in the generated report.</li>
    <li>HLAs are currently not included in PharmCAT.</li>
  </ol>
  <h3>D. CPIC Guideline Disclaimers and Caveats</h3>
  <ol>
    <li>A version of the following quoted disclaimer is part of each CPIC guideline and applies to the CPIC recommendations
      as used in PharmCAT. For the full description of potential benefits and risks, additional considerations (general and
      specific to gene-drug pairs), limitations, information about respective gene nomenclature systems, potential
      drug-drug interactions and clinical factors to consider, please see individual CPIC guidelines
      (<a href="https://cpicpgx.org" rel="nofollow">cpicpgx.org</a>).
      <ol>
        <li>"CPIC guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at
          the time they are written and are intended only to assist clinicians in decision-making and to identify questions
          for further research. New evidence may have emerged since the time a guideline was submitted for publication.
          Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified.
          Guidelines do not account for all individual variations among patients and cannot be considered inclusive of all
          proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care
          provider to determine the best course of treatment for a patient. Adherence to any guidelines is voluntary, with
          the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC
          assumes no responsibility for any injury to persons or damage to persons or property arising out of or related to
          any use of CPIC's guidelines, or for any errors or omissions." (PMID:
          <a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" rel="nofollow">27997040</a>)</li>
        <li>"Caveats: appropriate use and/or potential misuse of genetic tests. The application of genotype-based dosing is
          most appropriate when initiating therapy with a tricyclic. Obtaining a pharmacogenetic test after months of drug
          therapy may be less helpful in some instances, as the drug dose may have already been adjusted based on plasma
          concentrations, response, or side effects. Similar to all diagnostic tests, genetic tests are one of several
          pieces of clinical information that should be considered before initiating drug therapy." (PMID:
          <a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040" rel="nofollow">27997040</a>)</li>
      </ol>
    </li>
    <li>CPIC guidelines reflect the alleles/genotypes known and considered by the guideline authors for inclusion by the time
      of publication, however they may be updated online at
      <a href="https://cpicpgx.org" rel="nofollow">cpicpgx.org</a> and in the CPIC database in between publications. Additional alleles and/or more
      extensive allele definitions might exist by the representative gene nomenclatures for various genes.</li>
    <li>CPIC is a registered service mark of the U.S. Department of Health &amp; Human Services (HHS).</li>
  </ol>
  <h3>E. PharmGKB Disclaimers and Caveats</h3>
  <ol>
    <li>PharmGKB is a registered service mark of the U.S. Department of Health &amp; Human Services (HHS).</li>
  </ol>
</section>


</main>
</body>
</html>
